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Summary
The work presented in this thesis was concerned with the detection of anabolic drugs 
in the racing greyhound. The use of these substances in racing animals is prohibited 
by the National Greyhound Racing Club in the rules governing the sport. Prior to 
this study, little information existed regarding the metabolism of these anabolic 
agents in the racing greyhound or the detection of their administration.
This study initially established a greyhound metabolic unit and developed an 
experimental protocol based on fully trained racing greyhounds as the animal model. 
The unit and protocol were licenced by the Home Office for this purpose. Because 
of the lack of information in the literature, work was carried out to establish the 
normal urinary steroid profile in the racing greyhound and some basic information 
regarding steroid metabolism in the racing greyhound. Subsequently, the 
metabolism of selected anabolic steroids (nandrolone and boldenone) in the 
greyhound was studied, together with the effects of these exogenous steroids on the 
normal steriodal profile. Finally, the metabolism in the greyhound of another 
anabolic agent, clenbuterol, was examined.
Methodology was developed for the analysis of steroids in urine and plasma based on 
solid phase extraction, enzymatic hydrolysis, Sephadex LH-20 fractionation and 
qualitative and quantitative analysis by gas chromatography-mass spectrometry (GC- 
MS). The extraction protocols were assessed using radiolabelled steroids and found 
to be acceptable. Hydrolysis procedures were assessed by HPLC and found to be
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satisfactory. A variety of derivatisation reagents were evaluated to optimise the 
GC-MS procedure.
It was not possible to detect the presence of steroids in the urine of male greyhounds 
using full scan mass spectrometry. In female greyhounds, however, it was possible 
to identify the presence of a pregnane, an estrogen and two corticosteroids. 
Additional constituents were present which may also have been steroids but their 
identification could not be confirmed. Testosterone was shown to be present in 
greyhound urine using radioimmunoassay. Maximum concentrations of testosterone 
measured were approximately 25ng/mg creatinine and 10 ng/mg creatinine for two 
male greyhounds.
The metabolism and turnover of testosterone in the greyhound were investigated 
using labelled forms of the drug. Radiolabelled testosterone was administered to a 
male greyhound at a low dose, designed to increase the metabolic pool size of 
testosterone in the animal as little as possible. Plasma samples and complete urine 
collections were obtained. Elimination of the radiolabelled material from the plasma 
was rapid and approximately 40% of the dose was recovered in the urine by 7 days 
post dose. An apparent volume of distribution of 5.8 litres was calculated for 
testosterone.
A quantitatively significant dose of deuterium labelled testosterone (2 milligrams) 
was administered intravenously to a greyhound. The testosterone pool size for the 
animal was estimated by isotopic dilution at approximately 190pg.
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Two exogenous anabolic steroids (nandrolone and boldenone) were administered 
intramuscularly to two male racing greyhounds. Nandrolone was found to be present 
in predose urine and plasma samples indicating that nandrolone is in fact an 
endogenous steroid in the racing greyhound. Following administration of nandrolone 
to the two male dogs, levels of nandrolone in plasma rose from 30 and 60 ng/ml to 
over 100 ng/ml in both dogs. Elimination of nandrolone after a few days brought the 
plasma concentration back to the initial starting levels. Levels of endogenous 
steroids were depressed in plasma samples along with the concentration of creatinine 
excreted in the urine.
Boldenone was not detected in either plasma or urine samples following 
intramuscular administration. While depression of the endogenous profile did occur, 
it was less than that which occurred following dosing with nandrolone.
Clenbuterol is a beta-agonist drug that has been abused as an anabolic agent both in 
human sport and in livestock farming. Methodology was developed for the detection 
of clenbuterol in plasma and urine samples from the racing greyhound. Although the 
greatest sensitivity could be achieved using negative ion chemical ionisation-mass 
spectrometry in association with a heptafluorobutyrate derivative, the use of a 
simpler trimethylsilyl derivative and electron impact ionisation was found to be 
adequate and was considered more appropriate as a routine method. Clenbuterol was 
administered orally to one male and one female racing greyhound. Severe side 
effects were noted within 2 hours post dose and continued past 24 hours post dose. 
Peak plasma concentrations of clenbuterol occurred between 5-24  hours post dose
XI
and it was possible to determine the presence of clenbuterol in plasma and urine of 
the dogs for at least 8 days post dose.
It was concluded that the principal aims of the project had been achieved.
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Chapter 1: Drugs in Sport
Introduction
With the rewards for success in sporting events currently being so high, it is 
not surprising that competitors will do almost anything to gain an advantage over 
their opponents. To try and gain this advantage, individuals may roughen up one 
side of a cricket ball in an effort to increase the swing of the ball to catch out an 
unwary batsman, insist a game of chess is played on a board with green and red 
squares to try and disrupt the opponent’s concentration, as Bobby Fischer did in 
1972, or use chemical substances to allow an individual to gain an unfair physical 
advantage over other competitors. In the latter case, a person may take substances 
for short-term effects, for example sedatives, which can be used to reduce nerves or 
anxiety in snooker and archery, or use drugs, which are intended to give long-term 
benefits such as anabolic agents.
The use of chemical substances in an effort to gain an advantage is not a 
modem phenomenon. In the Third Century BC, Greek athletes ate hallucinogenic 
mushrooms \  Viking warriors used root extracts to induce berserker trances. In the 
last century in 1879, competitors in six-day bicycle races used caffeine, alcohol, 
nitro-glycerine, ether dropped on sugar cubes, strychnine pills, cocaine and opium. 
The Olympic marathon champions in both 1904 and 1908 had almost certainly taken 
strychnine.
In 1960, Knud Jensen of Denmark, a cyclist, died on the opening day of the 
Rome Olympics. Traces of ronicol (a vasodilator) and amphetamine were found in 
his body at the post-mortem examination. In 1967, the British cyclist Tommy 
Simpson died while competing in the Tour de France'. Like Jensen 7 years earlier, 
amphetamine was found in his body at the post-mortem. These tragedies and others 
led to the introduction of legislation in various countries and the introduction of 
dope testing for both Olympic events in 1968, the Winter Games at Grenoble and the
l
summer games at Mexico City. This legislation and dope testing has not, however, 
eliminated the use of drugs in sport.
The Use of Anabolic Agents in Sport
In 1973, Howard Connelly, the Olympic hammer champion in 1956 stated:- 
'the overall majority o f athletes I know would do anything and take anything 
short o f  killing themselves to improve their athletic performance. ’
To improve strength and muscle bulk, and consequently to improve their athletic 
ability, some individuals have used anabolic agents.
The effects of testosterone were first noted in the eighteenth century, when 
John Hall transplanted the testes of a cock to hen. The hen developed male 
characteristics. In 1849, Berthold showed that implanting gonads into castrated 
roosters could prevent the effects of castration. Various ‘magic potions’ then 
became available over the next 75 to 100 years and were primarily sold on the basis 
that they could help prevent ageing and maintain sexual potency. These potions 
ranged from injecting an aqueous suspension of guinea pig testicles to the 
transplantation of monkey testicles into human males in the 1920’s.
It was in 1930 that one of the first androgens was isolated. Androstenedione 
(15 mg) was isolated from 15,000 litres of urine. Soon after, testosterone was 
isolated and eventually synthesised in 1935. Experiments continued with 
testosterone throughout World War Two. It was given to German soldiers to 
increase their aggression and, ironically, to victims of the concentration camps to 
increase their strength and muscle bulk. Sporting use of steroids probably originated 
in the 1950’s. Dr John B Zeigler, the US weightlifting team doctor for the world 
championships in Vienna in 1954 claimed that the Russian team doctor told him that 
certain members of the Russian team were taking synthetic testosterone . Dr Zeiger 
started to use dianabol, a synthetic oral steroid developed by Ciba Geigy with a high 
anabolic/androgenic ratio3 with weightlifters but soon discontinued his involvement 
with steroids when he started to notice side effects in users such as the shrinking of
2
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testicles . The use and experimentation with anabolic steroids continued throughout 
the 1960’s. It was predicted by the Scottish Athlete David Jenkins that five of the 
top men in every sport would be using anabolic steroids by the Montreal Olympics3. 
The use of anabolic steroids was not only practised by individuals. Franke and 
Berendonk have published a review of the anabolic steroids used in the German 
Democratic Republic4.
As indicated earlier, testing for banned substances commenced in 1968 in the 
Olympic Games. It was not until the 1976 Olympics in Montreal that testing for 
anabolic steroids came into effect. The initial tests were carried out by 
radioimmunoassay following procedures developed by Professor Raymond Brooks 
of St. Thomas’ Hospital, London.
Even though the use of anabolic steroids could be detected analytically in 
1976, testosterone was not added to this list until 1982. A problem existed in 
determining the use of exogenous sources of this natural, endogenous steroid. It was 
noted that the ratio of the concentrations of testosterone and its inactive 
stereoisomer, epitestosterone (T/EpiT ratio) normally lay between 1:1 and 2.5:1 in 
humans. Testosterone use was said to have occurred if the T/EpiT ratio exceeded 
6: l5. The biochemical basis for this test depends on a negative feedback mechanism 
in the hypothalamus-pituitary-gonad axis, summarised in figure 1.1. The validity of 
this test has been challenged, notably in the case of the athlete Diane Modahl.
The detection of steroid use in sport is now a highly sophisticated process. 
The early presumptive radioimmunoassay tests have been replaced with gas 
chromatography-mass spectrometry, including the introduction of high resolution 
mass spectrometry for the 1996 Olympic Games in Atlanta, to provide the definitive 
answer which can stand up to scientific and legal scrutiny. Even though there is a 
wide variety of testing procedures in place, individuals still try to use anabolic agents 
to gain a competitive edge. In 1988, Ben Johnson of Canada was stripped of his 
Gold Medal in the 100m at the Seoul Olympics after testing positive for Stanozolol 
(Winstrol), a 17a-alkylated oral steroid. It has been alleged that he thought he was
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using dehydrotestosterone, which was believed to be undetectable in 1988, but his 
coaches and trainers provided him with stanozolol instead. In 1992, the British 
athlete Jason Livingstone was tested positive for Dianabol (methandrostenolone), 
one of the original anabolic steroids that was no longer popular due to its serious 
side effects. Recent studies have demonstrated the detection of stanozolol in hair, 
further advancing the window of detection to the length of the hair sample6.
Athletes turned to the use of other anabolic agents in order to try and evade 
detection. A popular agent was clenbuterol, a P-agonist. Originally used to treat 
asthma, the first use of this compound as an anabolic agent is credited to British 
athletes in 19887, and like all other performance enhancing drugs it was thought to 
be undetectable. In addition to its use in humans, it has been used illegally to 
increase muscle bulk in beef cattle. Very sensitive and specific methodology has
o Q
been developed for detection and analysis of clenbuterol in a variety of samples • . 
Again, the testing procedures have caught up with individuals who use drugs and the 
German athlete Katrina Krabbe was tested positive for clenbuterol while racing in 
South Africa.
Drugs like the anabolic steroids and clenbuterol are now gradually being 
replaced by compounds like hGH (human growth hormone), a 191 amino acid 
peptide, and iGF 1 and iGF2 (insulin like growth factor 1 and 2). It is also probable 
that as testing procedures are developed for these compounds, individuals will 
switch to other alternatives.
Conventional wisdom is that anabolic agents should not be used 
continuously, otherwise plateauing occurs, that is, after initial gains, the agents no 
longer exert their effect on the body. Consequently, a series of procedures have been 
developed to avoid plateauing10. The agents are used in cycles of four to twelve 
weeks, followed by a clear period, allowing the body to re-establish its normal 
conditions (e.g. liver function, normal steroid profiles). During the periods of drug 
consumption, individuals ‘stack’, ‘shotgun’ or ‘stagger’ the anabolic agents.
Stacking involves the use of two agents simultaneously, normally an oral steroid and
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an injectable steroid. Shotgunning involves the use of more than two agents 
simultaneously and staggering is the changing of the agents periodically. All these 
processes are designed to stop plateauing. There is little evidence to suggest that 
they work. A detailed description of the mode of action of steroids is given in later 
chapters. In addition to these procedures, many individuals use far larger doses of 
steroids than would be used normally, thereby increasing the risk of undesirable side 
effects.
Greyhound Racing in the United Kingdom
In the United Kingdom, there are two types of greyhound racing tracks.
There are the tracks which are regulated by the National Greyhound Racing Club 
(NGRC) and the "gaff’ or "flapping" tracks which in effect are independent tracks 
with no one body regulating the racing which occurs on these tracks. There were 38 
NGRC regulated tracks in the U.K., two of which were in Scotland: Shawfield 
Stadium in Glasgow and Powderhall Stadium in Edinburgh (now no longer in 
operation). As well as the two NGRC tracks, there are up to 14 flapping tracks in 
Scotland, mostly around the central belt. On each type of track the overall format is 
similar. There are ten to twelve races in each race meeting with each race normally 
containing six dogs. This number is not fixed as NGRC rules allow up to eight dogs 
in a single race and a race may be run with less than six greyhounds in the traps.
Prior to racing, each greyhound is subjected to time trials to establish a 
formbook. Once this form has been established, the greyhounds are graded and 
placed into races according to their form. A handicap system also operates at NGRC 
registered tracks where a greyhound may be given up to a 10 metre start over its 
rivals. At flapping tracks each dog is weighed, visually inspected and earmarked 
prior to each race. No more detailed examination of the animal is carried out.
At NGRC regulated tracks, a more detailed veterinary examination is carried 
out and a urine sample is taken prior to the race to screen for the presence of any 
illegal doping substance. As with other sporting bodies such as the Jockey Club and
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the International Olympic Committee, the NGRC has banned the use of substances 
that will either enhance or diminish the performance of a racing animal. The 
definition of an individual who is guilty of doping a greyhound is given as follows in 
the NGRC rulebook, rule number 174a n >
[A person is liable to disciplinary action if he/she]
i. has administered or attempted to administer or has allowed or caused to 
be administered or connived at the administration for any improper use to 
a greyhound of any quantity of a substance which, by its nature, could 
affect the performance of a greyhound the origin of which on or in the 
tissues, body fluids or excreta of a greyhound could not be traced to 
normal or ordinary feeding or care; or
ii. has had in his/her charge a greyhound which on examination under rules 
113, 116, or 173 showed the presence on or in its tissues or bodily fluids 
or excreta of any quantity of any substance which by its nature could 
affect the performance of a greyhound or which shows evidence in any 
way of the administration for any improper use, the origin of which 
cannot be traced to normal or ordinary feeding or care.
This statement covers a wide range of substances and includes caffeine and 
theobromine that are allowed in small quantities in other sports. For comparison, the 
International Olympic Committee rules provide a list of banned substances and 
doping methods and the Jockey Club rules state that it is illegal to administer a 
substance that will affect a named body system (e.g. the nervous system, the 
cardiovascular system).
This first urine sample is screened and tested at the trackside. If any trace of 
a compound is detected which contravenes the above rule, the greyhound is 
withdrawn from the race meeting immediately. In a further attempt to eliminate the 
chemical manipulation of the greyhounds, in the event of a greyhound not
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performing to its established form, a second screen is performed based on a post­
race sample of blood or urine. This latter sample is sent to the reference laboratory 
at Newmarket, formerly the Department of Forensic Medicine and Science at the 
University of Glasgow, where it is analysed by radioimmunoassay (RIA), thin layer 
chromatography (TLC), high performance liquid chromatography (HPLC) gas 
chromatography (GC) and gas chromatography-mass spectrometry (GC-MS). Table 
1 lists the substances found in the samples examined in the reference laboratory in 
1988. These results came from 637 samples tested at the reference laboratory, with 
5.81% of the samples giving positive results.
If a racing animal is found to be positive for a banned substance, the 
owner/trainer can be fined and his racing licence can be suspended for a period of 
time.
Aims of Study
To implement a successful doping control program for anabolic agents, a 
certain minimum level of information is required, for example the normal urinary 
and plasma steroid pattern in a racing greyhound, the effects of anabolic steroids on 
this pattern and pharmacokinetic data of the various compounds used. Very little 
data exists on these topics for the racing greyhound. The racing animals may display 
significantly different patterns of responses to anabolic agents when compared not 
only to other species but also to other breeds of dogs due to their physiology and 
training conditions e.g. little or no body fat, high protein diet, active training regime. 
It is necessary to establish this basic information under controlled circumstances to 
allow appropriate control measures to be introduced. The aims of this project could 
therefore be summarised as follows
1. to establish a metabolic unit for greyhounds in which the dogs would be 
trained in an identical manner to racing animals;
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2. to characterise the normal urinary and plasma steroid profiles for the 
racing greyhound;
3. to obtain some basic pharmacokinetic information regarding steroid 
metabolism in the racing greyhound;
4. to examine the pharmacokinetics of specific anabolic agents in the racing 
greyhound;
5. to examine the effects of these exogenous steroids on the normal steroid 
profile;
6. to examine the pharmacokinetics of other anabolic agents (namely 
clenbuterol) in the racing greyhound
8
Drug Number of 
Positive Results
Caffeine 13
Chlorpromazine 4
Cyclizine 4
Quinalbarbitone 4
Quinine\Quinidine 3
Primidone and Phenobarbitone 1
Amphetamines 1
Ibuprofen 1
Caffeine, Theobromine and Diazepam 1
Millophylline 1
Diazepam and Diphenhydramine 1
Paracetamol 1
Procaine 1
Glutethimide 1
Total 37
Table 1. Drugs Reported Present in the Urine of Racing 
Greyhounds Tested at the Reference Laboratory at the University
Of Glasgow in 1988.
Chapter 2 Steroid Hormones 
Steroid Nomenclature and Structure
All steroids are based on the cyclopentaperhydrophenanthrene structure.
There are five main groups of mammalian steroids. These are the 
cholestanes (C27), cholanes (C24), pregnanes (C21), androstanes (C l9) and 
oestranes (Cl 8). The basic structures of these compounds and the numbering system 
employed are presented in Figure 2.1. These compounds are all derived from 
cholesterol. In naturally occurring steroids, these basic structures can be modified in 
three main ways;
i. the addition of hydroxyl groups.
ii. the addition of carbonyl groups.
iii. the introduction of unsaturation into the ring system.
The position of the modification is noted by number and prefixes and 
suffixes used to show the presence of various hydroxyl and carbonyl substituents. If 
there is more than one group which can act as a suffix, a series of rules have been 
established and a specific order of preference has been laid down by the 
International Union of Pure and Applied Chemistry (IUPAC) and the International 
Union of Biochemistry12,13. As well as the systematic naming system, there exists a 
large number of names which originated in the historical development of the field.
Stereoisomerism also commonly occurs at various key locations throughout 
the molecule, notably the orientation of the hydrogen atom on C5. When there is a 
hydroxyl group present within the molecule, there is the opportunity for the group to 
take up one of two stereochemical positions. The group can lie on either the alpha 
or beta side of the ring structure (Figure 2.2). This stereochemical difference can 
dramatically influence the physiological and biochemical effects of a particular 
steroid. Testosterone (17(3-hydroxy-androst-4-ene-3-one) is a potent androgen while 
epitestosterone (17a-hydroxy-androst-4-ene-3-one) is inactive.
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Figure 2.1a
Figure 2.1b
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Figure 2.2 Asymmetry in the Steroid Skeleton
Basic Mechanisms of Hormone Action
Three possible mechanisms for the action of hormones within a biological 
system have been proposed 14. These are illustrated by Figure 2.3
In the first mechanism, the hormone binds directly to a rate limiting enzyme, 
alters the conformation of the enzyme and as a result either activates or deactivates 
the enzyme. This was the earliest of the three mechanisms proposed. It was found 
to present too simplified a view of the mode of hormone action and the concept of a 
receptor was introduced.
Mechanism 2 involves the binding of the hormone to a receptor that in turn 
binds to a rate-limiting enzyme to cause the metabolic changes. This mechanism 
also appears to be too simple an explanation for the mode of action of hormones.
The third and most complex mechanism involves at least four components. 
Initially, the hormone binds to a receptor. This hormone-receptor complex (H-R) 
then binds to an acceptor, which in turn exerts its effect on a rate-limiting enzyme. 
The mechanism of steroid action is thought to follow this third model.
Mechanism of Steroid Action
The current model of steroid action is similar to the mechanism proposed by 
Gorska et al and Jensen et a l15,16. It is described diagrammatically in Figure 2.4.
Steroids exist in the bloodstream in one of two forms, free or protein bound. 
When existing in the free form, they can passively diffuse through the outer cell 
membrane into the cytosol and pass into the nucleus of the cell. Once within the cell 
nucleus, the steroid can bind reversibly to a receptor protein (KD =1010 to 10-8) and 
form a stable complex. The receptor proteins have been found to be exceptionally
17steroid- and tissue-specific and there are thought to be around 10,000 to 100,000 
molecules of each receptor present per cell. Once bound, the steroid causes 
conformational changes to the receptor which allow the steroid-receptor complex to 
bind reversibly to the chromatin at a site called the Steroid Response Element (SRE)
13
Mechanism 1
Mechanism 3
Figure 2.3 Proposed Mechanisms for the Action of Hormones
Hormone 
: Receptor 
Acceptor 
Enzyme
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which acts as a transcriptional regulator. This regulatory effect is achieved by 
altering the transcription rates of steroid responsive genes or, occasionally, the post 
transcription process affecting a change in the levels of specific mRNA and/or 
proteins 18.
Unlike some other hormones that exert a very rapid response, e.g. 
adrenaline, the time period over which steroid action occurs is quite long. It takes 
around four minutes for the steroid to diffuse to the nucleus and bind to the receptor 
protein and 4-5 minutes for the steroid-receptor complex to become attached to the 
steroid response element. Once bound to the SRE, it can be up to four hours for the 
Pre-mRNA to be formed, up to 4 hours for the mRNA to be transcripted and 4-8 
hours for the levels of enzymes and proteins to be affected, either stimulating or 
diminishing production levels. The major physiological effects of steroids on an 
individual are not observed until 12-24 hours after dosing.
Structure of a Steroid Receptor
In-depth studies have been carried out on progesterone receptors in chickens 
19,20 and rabbits 2I, glucocorticoid receptors in mouse 22, human23, and ra t24, and 
oestrogen receptors in chicken 25, frog 26, human 27, mouse 28 and rainbow trout29 
As a result of these studies, it has been proposed that there are four distinct regions 
or domains in each receptor (Figure 2.5). The N-terminal region (Domain 1) of the 
receptor is primarily concerned with the activation of transcription, Domain 2 is the 
DNA-binding domain and contains two ‘zinc fingers’ which wrap around the DNA 
helix, Domain 3 is termed the hinge domain and is involved in nuclear localisation, 
transcription and dimer formation and domain 4, the steroid binding domain is 
where the steroid actually binds to the receptor. When the steroid binds with the 
receptor, a conformational change occurs to the receptor and this allows the central 
region of the receptor to bind to the DNA and allow the hormone to exert its effects.
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Figure 2.4 Mechanism of Steroid Action.
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Figure 2.5 Structure of Steroid Receptor
Biosynthesis of Steroids.
In vivo, the mammalian synthesis of steroids occurs via cholesterol. It has 
become accepted that a small but quickly replenished pool of cholesterol exists 
which does not come from circulating cholesterol but which is derived mainly from 
synthesis from acetyl units. Figure 2.6 summarises the synthetic processes.
Three molecules of acetyl CoA combine to form mevalonic acid, a six 
carbon molecule (C6). This is decarboxylated and dehydrogenated to form 
isopentylpyrophospate, the basic C5 isoprenoid building block. Three of these C5 
units combine to give famesyl pyrophosphate (Cl 5) and two of these famesyl units 
join to give squalene (C30). Squalene is cyclised to lanosterol, which is 
subsequently modified by demethylation, reduction and double bond re-arrangement 
to cholesterol.
Conversion of Cholesterol to Pregnenolone
3p-Hydroxy-A5-pregnan-20-one (pregnenolone) is now considered to be the 
precursor of C21, C l9, and C18 steroids. It is thought that cholesterol undergoes a 
two-stage process of conversion to 20,22-dihydroxycholesterol followed by side 
chain cleavage to give pregnenolone and a C6 unit, 4-methylpentanal, which is 
rapidly converted to isocaproic acid (Figure 2.7). There is uncertainty as to which of 
the two hydroxylations take place first. Experimental evidence from the late 1950’s 
suggested that C20 was the first position to be hydroxylated followed by 
hydroxylation at C22. During the past twenty years however, several hydroxy- and 
epoxy- derivatives of cholesterol of known stereochemistry have been synthesised 
and Hume et al. have provided evidence for the initial hydroxylation to take place on 
C22 . Further studies on this system have shown the presence of three enzymes, 
two hydroxylases and one lysase with a requirement for molecular oxygen and 
NADPH in association with two proteins, adrenodoxin and adrenodoxin reductase. 
Simpson provides a detailed review of this work .
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Figure 2.6 Synthesis of Cholesterol from Acetyl CoA.
The Biosynthesis of Androgens
The synthesis of androgens can occur in the testes, adrenal cortex, ovaries 
and the placenta with the largest portion of biosynthesis occurring in the Leydig 
Cells in the testes of males. The synthesis of androgens has been extensively studied 
in many species including humans and dogs. There are two possible closely related 
pathways for the synthesis of testosterone in the body; the A5 pathway, involving 3(3- 
hydroxy-A5 steroids, which appears to be the favoured path in human and dog 
biosynthesis, and the A4 pathway, favoured in rat and mouse, involving 3-oxo-4-ene- 
steroids (Figure 2.7).
A5 Pathway.
Pregnenolone is converted to 17a-hydroxypregnenolone and is followed by 
side chain cleavage to give dehydroepiandrosterone (DHA). Both these steps have a 
requirement for NADPH and oxygen. DHA is converted to androstenediol and the 
final stage involves the re-arrangement of the A5 double bond to A4 and the 
dehydrogenation of the hydroxy group at position 3 to give testosterone.
A4 Pathway
Except for the initial stage, the A4 pathway follows a similar pattern to the A 
5 pathway. Pregnenolone is transferred to progesterone by the conversion of the 
saturated A-ring to a 4-ene-3-one structure. This is hydroxylated at position 17 to 
give 17a-hydroxyprogesterone. Following side chain cleavage to give 4-androsten- 
3,17-dione, the final stage of the synthesis is the reduction of the ketone group at 
position 17 to give testosterone. As in the A5 pathway, the two stage conversion of 
progesterone to 4-androsten-3,17-dione has a requirement for NADPH and oxygen.
There exists the possibility for the interconversion of 3(3-hydroxy-5-ene 
steroids to 3-oxo-4-ene steroids, i.e. the A5 to the A4 pathway. It was initially 
thought that there were two separate enzymes required to accomplish this 
conversion; a 3 p-hydroxy NAD oxidoreductase and a 3-oxosteroid-4,5-isomerase. It 
has more recently been suggested that these enzymes form part of a complex 32,33.
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The Biosynthesis of Corticosteroids
Using radiolabelled precursors, the basic pathways for the synthesis of 
corticosteroids have been established. The initial stage appears to be the conversion 
of pregnenolone to progesterone. Once progesterone has been formed the synthetic 
pathway can take one of two routes. If progesterone is hydroxylated at C21, 
deoxycorticosterone (DOC) is formed. This can be followed by hydroxylation at 
Cl 1 to give corticosterone. Corticosterone can be converted to aldosterone, the 
major mineralocorticoid by an 18-hydroxysteroid dehydrogenase.
If progesterone is hydroxylated at C17 to give 17-hydroxyprogesterone, this 
leads to a further branching of the system. The 17-hydroxyprogesterone can be 
diverted into androgen synthesis (see above) or can be hydroxylated again at C21 to 
give 11-deoxycortisol before a further hydroxylation to give cortisol (Fig 2.8). All 
the enzymes in this system have a requirement for NADPH and oxygen.
The Biosynthesis of Oestrogens
In humans, there are four main organs involved in the production of 
oestrogens. These are the ovaries34, the testes35, the adrenal cortex and the 
foetoplacental unit. The main oestrogen synthesised is oestradiol along with 
significant amounts of oestrone and oestriol. The initial stages in oestrogen 
synthesis are identical to the A4 and A5 pathways described above and illustrated in 
Figure 2.7.
The conversion of 4-androstenedione and testosterone to 17p-oestradiol 
follows similar paths. The methyl group on C19 is oxidised and is followed by 
conversion to a phenolic compound (Figure 2.9). The removal of the carbon at C19 
appears to be achieved by the hydroxylation of the A-ring at C2 followed by non- 
enzymatic aromatisation36,37. As with the synthesis of androgens and corticosteroids, 
there is a requirement for NADPH and oxygen. Although attempts have been made 
to characterise the aromatase system, the results have not yet been successful38,39.
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Regulation of Steroidogenesis
There appear to be many factors affecting the regulation of steroidogenesis. 
The trophic hormones, e.g. adrenocorticotrophin (ACTH), exhibit regulatory effects 
and it has been shown that the presence or absence of various endogenous steroids 
can affect the hydroxylases of steroid synthesis.
Effects of Adrenocorticotrophin (ACTH) on Steroidogenesis
ACTH is a polypeptide secreted by the anterior pituitary and contains thirty- 
nine amino acids. It has been shown that only the first twenty-four amino acids from 
the N-terminal end are essential and that the remaining fifteen are thought to be 
associated with an immunological function.
The proposed mechanism of action of ACTH has been described40. The 
mechanism appears to follow a cascade system. ACTH is released by the anterior 
pituitary and binds to a receptor protein on the wall of the target cell. This triggers 
the enzyme adenylate cyclase to convert adenosine triphospate (ATP) to cyclic 
adenosine monophosphate (cAMP). The cAMP travels through the cell and in turn 
binds to the regulatory subunit of a protein kinase. Once freed from the regulatory 
subunit, the protein kinase phosphorylates cholesterol ester hydrolase 41 that 
consequently releases cholesterol from storage. The free cholesterol is transported 
into the cell mitochondria and interacts with Cytochrome P-450. It has been shown 
that the transfer of cholesterol across the organelle membrane is dependent on the 
presence of cycloheximide 42. Once the side-chain is removed, pregnenolone is 
transported back into the cytosol for further enzymatic action.
Levels of circulating ACTH are regulated by means of a negative feedback 
loop to the hypothalamus. For ACTH to be released from the pituitary, 
corticotrophin releasing factor (CRF), a forty-one amino acid peptide hormone, must 
be released by the hypothalamus 43 44 The release of this factor is inhibited by the
25
presence of circulating steroids and it has been shown that CRF only affects the 
release of ACTH and no other circulating hormone levels 45.
Regulatory Effects of Gonadotrophins on steroidogenesis
In humans, there are two main protein hormones that are secreted by the 
pituitaiy. These are luteinising hormone (LH) and follicle stimulating hormone 
(FSH). The modes of action, release and regulatory effects of these gonadotrophins 
are similar to those of ACTH in that their release is triggered by a smaller peptide, 
gonadotrophin releasing hormone (GnRH) from the hypothalamus and their action is 
via the cAMP protein kinase mechanism described above. A negative feedback loop 
exists to the hypothalamus that regulates the release of GnRH. It has been shown 
that androgens participate in this negative feedback loop, as there are increases in 
the levels of secretion of the gonadotrophins following castration in rats 46. LH is 
thought to regulate androgen synthesis and FSH is thought to regulate oestrogen 
synthesis.
Regulation of Steroidogenesis by Endogenous Steroids
A large volume of work has been concerned with investigating the effects of 
endogenous steroids on the biosynthetic pathways. It appears that the later products 
of these pathways inhibit the earlier stages of the synthesis (Fig 2.10). For example, 
testosterone inhibits the conversion of cholesterol to pregnenolone, pregnenolone to 
17-hydroxypregnenolone, 4-androstenedione to testosterone, DOC to corticosterone 
and 11-deoxycortisol to cortisol. It does not however inhibit its own conversion to 5 
a-DHT. This would result in a build up in the amount of testosterone present and 
inhibit the previous stages to a greater degree.
Metabolism of Endogenous Steroids
The purpose of metabolism is normally twofold; to reduce the physiological 
activity of a compound and to increase the ability of an organism to excrete the 
material from its system. In the case of steroids, the reduction in physiological
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Figure 2.10 The Inhibition of Steroid Synthesis by Steroids
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activity goes hand in hand with an increase in hydrophilicity of the compounds.
Four major catabolic routes have been established.
1. The reduction of the C4 double bond and the accompanying reduction of 
the C3 oxo group.
This catabolic process can result in the formation of up to four metabolites, 
all stereoisomers. These are 5a-3p, 5a-3a, 5(3-3(3, and 5p-3a where the 
stereochemistry of position 5 relates to the hydrogen atom and position 3 to the 
hydroxy group (See Figures 2.1 and 2.2). In man the 3a-5(3 hydroxysteroids 
predominate but in many animals the 3 p-hydroxysteroids are to the fore. It appears 
as if this catabolic step is a two-stage process. The initial stage involves the 
reduction of the double bond by either a 4-en-5-a-reductase or a 4-en-5-P-reductase 
and is followed by either a 3a- or a 3P-hydroxysteroid dehydrogenase.
2) The reduction of the C20 oxo group to a secondary alcohol.
In a similar route to the previous catabolic pathway, the C20 oxo group is 
reduced by a 20a- or a 20p-hydroxysteroid dehydrogenase. It is thought that the 
20a form predominates slightly over the 20p isomer in man.
3) The oxidation of the 17-hydroxy group.
The 17-hydroxy group is converted to the 17-oxo group by either a 17a- or a 
17p- hydroxysteroid dehydrogenase.
4) Hydroxylation throughout the ring system.
It is possible for some corticosteroids, for example cortisol, to become 
hydroxylated on C6 or C l6. These hydroxylations form quite polar molecules 
and allow the compound to be excreted from the system in an unconjugated form 
(see urinary excretion below).
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Figure 2.11 Metabolism of Testosterone
The metabolism of testosterone is summarised in Figure 2.11 and shows the 
combination of two of the catabolic processes described above. Testosterone is 
initially oxidised at the hydroxy group on C l7 to give 4-androstenedione. This then 
undergoes the first catabolic process described and can give rise to up to four 
metabolites; androsterone, epiandrosterone, etiocholanolone and epietiocholanolone.
Excretion of Steroids
There are two major routes of excretion. These are urinaiy and biliary and 
have been the pathways most examined. Excretion of steroids has also been 
examined in other body fluids, e.g. saliva, but levels of excreted compounds have 
been found to be low.
1) Urinary Excretion
Almost all steroids, except the polyhydroxylated metabolites, are too 
hydrophobic to be excreted directly. To overcome this problem, the steroids are 
converted to glucuronide or sulphate conjugates.
Glucuronidation
Glucuronidation involves the addition of a molecule of glucuronic acid to 
functional groups within the target molecule. In steroids, this target group is 
normally a hydroxyl group.
Glucose-1-phosphate is combined with uridine triphosphate (UTP), 
employing the enzyme UDP-glucose pyrophosphorylase, to give uridine diphosphate 
glucose (UDP-glucose). The UDP-glucose molecule is then dehydrated using UDP- 
glucose dehydrogenase and NAD+ to give UDP-glucuronic acid. This compound 
then combines with a functional group on the target molecule, using UDP- 
glucuronysl transferase, to give UDP and the glucuronide conjugate. Work has
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shown that the 17-oxo steroids are primarily excreted as the glucuronide conjugate 
with less than 10% excreted by other routes, mainly sulphates 47 48.
Sulphation
Initially, the conversion of steroids to sulphates was thought only to be a 
mechanism to allow the conjugates to be excreted via the kidneys. The use of 
radiolabelled steroids and the examination of DHA sulphate concentrations in 
arterial blood going into the adrenals and venous blood leaving the adrenals showed 
that these organs were synthesising the conjugate 49.
The sulphate group reacts initially with ATP to produce APS, adenosine-5'- 
phosphosulphate and pyrophosphate. The APS combines with a second molecule of 
ATP under the influence of ATP kinase to give PAPS, 3'-phosphoadenosine-5'- 
phosphosulphate and ADP. Finally PAPS combines with the hydroxyl group on the 
steroid to give the sulphate, PAP, 3',5'-phosphoadenosine and a proton.
The purpose of steroid sulphates in the blood stream is subject to speculation. 
They may act as a circulating store of steroid precursors50 because the sulphates are 
not removed so quickly from the blood supply as free steroids.
Biliary Excretion.
Although the principal route of excretion is urinary, a significant amount of 
steroids can be excreted via the bile. Sandberg and Slaunwhite51 gave human 
volunteers radiolabelled testosterone and recovered 89% of the dose in the urine and 
6% of the dose in the faeces. These steroids tend to be excreted as conjugates and it 
has been suggested that they can be classified into three groups, depending on the 
length of time it takes for them to be eliminated from the body52. Group ID steroids 
include cortisol and members of this group tend not to be eliminated to any 
significant degree in the bile. Group II steroids include testosterone and, as stated 
above, are excreted in the bile. Group 1 steroids include oestrone and oestradiol 
and it may take up to five days for radiolabelled metabolites to be recovered from
31
the urine and the faeces . This prolonged period of elimination has been attributed 
to enterohepatic recirculation that occurs when a compound is excreted via bile.
The bile passes into the gastrointestinal tract and the compounds are re-absorbed 
from the small intestine and enter the circulation of the organism for a second time, 
thus giving a second "dose" of the material. The majority of the steroids found in 
bile are conjugated and unsaturated while almost all the steroids found in faeces are 
free and saturated. It has been suggested that intestinal bacteria, probably in the 
caecum, metabolise the conjugated biliary steroids and it is the free steroids that are 
re-absorbed. The re-absorbed material can then be eliminated from the body a 
second time and may follow either primary route of excretion, and consequently be 
subject to further episodes of recirculation.
Anabolic Androgenic Steroids (AAS)
The principal androgenic steroid in the male is testosterone and in humans, a 
healthy young male will synthesise approximately 7 milligrams per day. During 
puberty, androgens control the growth of the primary sex organs in the male. All 
androgens also have an anabolic effect. This anabolic effect promotes an increase in 
muscle protein, accompanied by an increase in urinary creatinine, decrease in 
urinary nitrogen but no increase in blood urea. These result in a positive nitrogen 
balance, caused by an increase in metabolic nitrogen pool. Changes in bone 
structure and levels of enzymes associated with protein metabolism also occur and 
this gives rise to the characteristic growth during puberty. Clinically, the androgenic 
properties of certain steroids are used in replacement therapy in males suffering from 
hypogonadal disorders, in adolescent males with delayed puberty or growth, and in 
females androgens can be useful in the management of breast carcinomas. The 
anabolic properties of steroids are used to build up muscle bulk and cause a positive 
nitrogen balance in individuals who may be in a weakened state.
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It is not possible to have an androgenic steroid that does not have an anabolic 
effect and vice versa. It is however possible to synthesis a steroid with a high 
anabolic/androgenic ratio i.e. maximise the anabolic effects while minimising the 
androgenic effects. This ratio can be assessed by determining the relative changes in 
the weight of the levator anti muscle and the seminal vesicles in 21 day old castrated 
rate and expressing these changes as a ratio. The higher the ratio, the higher is the 
anabolic/androgenic ratio.
It is for the anabolic effect that steroids are primarily used in sport, in order 
to increase muscle bulk and strength, and to promote tissue repair and recovery 
following damage caused by intensive training or competition. It has been reported 
that individuals will take doses far in excess of the normal therapeutic amounts to 
achieve the desired anabolic effect. Testosterone is the primary androgenic/anabolic 
steroid produced by males. If testosterone is taken orally it is subject to extensive 
first pass metabolism and consequently can cause little effect in the body. 
Testosterone exhibits a plasma half-life of between 10 and 21 minutes in humans in 
the blood. It is metabolised to androstendione that exhibits only weak 
androgenic/anabolic properties. If unmodified testosterone is given parenterally, it is 
absorbed from the injection site and again is rapidly metabolised. Chemical 
modification of the structure of the androgen nucleus overcomes these problems and 
can produce anabolic steroids which are far more effective both as anabolic agents 
(i.e. high anabolic/androgenic ratio) and which have a far longer action. There are 
three general ways in which the nucleus can be altered to produce these effects:
1. esterification of the 17(3 hydroxyl group
2. alkylation of the 17a position
3. modification of the ring structure
Table 2.1 lists some of the synthetic anabolic steroids commercially 
available. It is possible to use only one of the above chemical modifications or all
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three to create an effective anabolic agent. The 17a alkylated steroids are effective 
orally. They are only slowly metabolised by the liver and consequently are not 
subject to extensive first pass metabolism. These oral steroids include 
methyltestosterone (Android) stanozalol (Winstrol) and oxandrolone (Anavar). For 
effective parenteral administration, esters of the anabolic agents are used. The esters 
are suspended in an oily base and, once injected, are slowly absorbed from the depot, 
and hydrolysed to give the free steroid. In humans, an injection o f200 mg of 
testosterone enanthate will give peak serum levels between 1 and three days after 
injection with levels falling to normal during the next 10-41 days. Other routes of 
administration are available (transdermal patches and long term implants54) but these 
are less liable to be used covertly.
Metabolism of Exogenous Anabolic Steroids.
A large body of information exists regarding the metabolism of anabolic 
agents in mammals. Table 2.2 summarises the principal metabolites of some of the 
more common anabolic/androgenic steroids in various species. The metabolism of 
steroids by the racing greyhound will be covered in detail later in this chapter.
Major advances in technology have allowed a more detailed elucidation of 
the metabolic patterns of steroids. Houghton et al in 1978 identified two metabolites 
of 19-nortestosterone in horse urine following the administration of nandrolone and 
nandrolone esters, using packed column gas chromatography mass spectrometry61. 
Later studies by Masse et al.63 and Schanzer et al.64 utilised capillary gas 
chromatography-mass spectrometry and identified 12 and 11 metabolites of 
stanozolol respectively. Both groups of authors concluded that almost all of these 
metabolites were hydroxylated and that the great majority was excreted as 
conjugates. Muck and Henion used liquid chromatography-mass spectrometry (LC- 
MS) to examine the metabolism of stanozolol in humans and horses65. Six 
metabolites were identified in human urine but only four in equine urine. As with 
the previous studies, all the metabolites were hydroxylated.
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Inter species variations do exist and can be quite marked. The principal 
metabolite of trenbolone (17p-hydroxy trenbolone) in bovine urine is 17a- hydroxy- 
trenbolone. In the rat, however, the principal metabolites are trenbolone itself (17(3- 
hydroxy trenbolone), 16-hydroxy-trenbolone and a 17-keto metabolite66. Care must 
therefore be exercised when extrapolating between species. Individuals who use 
anabolic agents for doping in sport also use quantities of steroids far in excess of 
normal therapeutic doses. This again may disrupt the excretion patterns of 
exogenous steroids. It is not ethically possible to repeat under controlled 
circumstances the use of such large doses of anabolic steroids.
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Schanzer and Donike have published details of the metabolism of a large number of 
synthetic steroids in man67. They detail the principal metabolites of 20 steroids, 
possible routes of preparation of authentic reference material and chromatographic 
data for the parent compounds and principal metabolites.
Side Effects of Anabolic/Androgenic Steroids
As indicated earlier, it is not possible to develop a purely anabolic steroid. 
Karch, in his book ‘Pathology of Drug Abuse68, provides a review of the undesirable 
and unwanted side effects of anabolic steroid abuse in humans and some of these 
side effects are listed in Table 2.3. He divides the side effects and changes into four 
categories: social, physical, mental and clinical. Many of the listed changes apply to 
other species, and while it is possible that horses and greyhounds suffer social and 
mental changes, these effects can be difficult to assess.
Some of the physical changes listed can be attributed to the normal 
androgenic/anabolic activity of the steroids. The dangers associated with H a- 
alkylated steroids concerning their ability to cause severe liver damage have been 
known for a long time69. The clinical changes are liable to be caused by the 
interference in the normal regulatory feedback systems for endogenous steroids. The 
mechanisms by which the mental changes occur have not yet been established.
Some of these mental changes (increased aggression and manic episodes) have been 
grouped together and individuals who use anabolic steroids have suffered from a 
phenomenon known as ‘roid rages’. Individuals who suffer from these ‘roid rages’ 
are reputed to be prone to violent outbursts of temper and/or aggression resulting in 
serious injury or death to others. The defence of ‘roid rage’ has been used in the 
USA, and in Scotland, individuals have tried to defend themselves from a charge of 
homicide by stating that their assailant was suffering a ‘roid rage’ when they were 
attacked. In the latter case, the defendants were eventually found guilty of culpable
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homicide and sentenced to 8 years in prison, even though the metabolites of 
nandrolone were identified in the urine of the murdered individual.
Greyhounds and Steroids
Very little information exists on steroids and greyhounds. Richkind and
7 0Enqvist examined the levels of corticosteroids in beagles and greyhounds using 
competitive protein binding. From their examination of six greyhounds, they 
concluded that the average concentration of corticosteroids was 18 ng per millilitre 
of plasma in both dogs and bitches. There were no significant differences between 
the sexes nor was there any significant diurnal variation.
In one of the few published papers on anabolic steroids and greyhounds,
71Pemberton looked at the effect of various compounds on greyhounds, including the 
anabolic steroid nandrolone. He states that 25 mg of nandrolone phenylpropionate 
intramuscularly caused a weight gain of approximately 1-2 kilograms per 2 weeks in 
female dogs. This body weight increase ceased after 2-3 kilograms had been gained. 
Weight gain exhibited by male dogs was less significant and Pemberton suggested 
that a cycle of one month on, one month off, would be more effective for dogs. He 
also examined the heart weight (g) to body weight (kg) ratio (Hwt/Bwt) in one dog 
and one bitch. The specific animals were chosen as they did not seem able to win a 
race. Following treatment with anabolic steroids, the dog’s Hwt/Bwt increased from 
10.1 to 11.6 and the female’s from 10.9 to 13.2. In addition, both animals started to 
win races.
One of the noted side effects of anabolic steroids is that when they are 
administered to growing individuals, the epiphyses may close up and stunt the 
growth of an individual. Pemberton states that he has never come across a case 
where this has occurred in greyhounds, but he has seen some animals that appeared 
to grow far too large due to the anabolic effect. Various blood parameters were also 
examined, and the biochemical changes that occurred were similar to those in 
humans, e.g. increased cholesterol.
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Social Obsession about health 
Large amount of time in gyms
Large amount of food supplements and food substances 
High calorie intake
No abuse of other drugs (including alcohol.)
Physical Rapid weight gain and muscle development 
Increased body hair and deepening of voice 
Acne 
Hair loss
Breast enlargement (males)
Testicular atrophy 
Difficulty in urinating.
Elevated blood pressure 
Stomach upsets 
Jaundice (liver damage)
Oedema of extremities
Mental Changes Increased aggression 
Hyperactivity 
Auditory hallucinations 
Paranoid delusions 
Manic episodes 
Depression and anxiety 
Panic disorders. 
Suicidal thoughts
Clinical changes Decreases in HDL cholesterol, LH, FSH and TSH, T3 & T4 
Increases in liver enzymes, haematocrit, LDL cholesterol, 
triglycerides, glucose
Table 2.3 Side effects o f anabolic/androgenic steroid use
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There were however significant side effects. Virilisation occurred in the 
bitches along with suppression of oestrus, changes in sexual behaviour (rejection of 
a mate), occasional lack of enthusiasm to chase (for some anabolic steroids), 
increased aggression and a tendency to fight while racing. In males, testicular 
atrophy (with a 6-12 month recovery period) and increased aggression occurred.
The side effects are similar to those found in humans and perhaps greyhounds can 
suffer a ‘roid rage’ like humans.
All the results reported by Pemberton appeared to be subjective in nature. 
There is no mention in the paper of systematic study or the use of control animals.
In his experiments with dosing the greyhounds, two animals were used. 
Unfortunately, no indication is given of the prevalence of the side effects mentioned 
and very little detail is given regarding the racing form of the greyhounds prior to 
treatment with anabolic steroids, which apparently improved their racing ability.
Some attempts have been made to examine systematically the metabolism 
and excretion of anabolic agents in the racing greyhound. Brockwell et al. 
attempted to determine the metabolism of certain anabolic agents (testosterone, 19- 
nortestosterone, 1,2-dehydrotestosterone) in greyhounds. The authors state that few 
publications were available regarding the metabolism of steroids in dogs and those 
that were available were primarily concerned with testosterone metabolism and bile 
metabolites. The authors gave mixtures of unlabelled and deuterium-labelled 
testosterone, 19-nortestosterone and 1,2-dehydrotestosterone to a castrated dog, 
intramuscular injections of boldenone undecylenate to an intact dog, and 19- 
nortestosterone and a mixture of testosterone esters to an intact bitch. Although the 
authors were able to identify some metabolites of testosterone and 19- 
nortestosterone, they concluded that excretion of the dosed steroids in urine was low 
and that immunoassay for the detection of steroids in urine was of little use. No 
attempt was made to try and establish a normal urinary steroid profile.
A related paper by the same group of authors concerning the detection of 19- 
nortestosterone in greyhound urine provided little information regarding greyhounds
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and was concerned mainly with the application of an immunoassay for the detection 
of 19-nortestosterone in urine samples of horses .
Beta 2 Agonists
Beta agonists are now banned under IOC regulations because of their reputed 
anabolic properties. Table 2.4 lists some of the p-2 agonists currently available. An 
agonist is simply a substance that activates a receptor and beta 2 is the designation of 
the receptor that is activated. Beta 2 receptors belong to the adrenoceptors of which 
there are five types, alpha l(a-l), alpha 2 (a-2), beta 1 ((3-1), beta-2(P-2) and beta 3 
(P-3). Attribution of a specific receptor to a specific class is dependent on that 
receptor’s response to specific agonists.
Originally developed to aid in the treatment of asthma sufferers, the P-2 
agonists are thought to have anabolic or re-partitioning properties. Their use in 
cattle was reported in 1984 and the first use of p-2 agonists in humans is attributed 
to British athletes in 1988. Although the mechanism of anabolic action has not yet 
been explained, the basic mechanism of action of the adrenoceptors has been 
established, a-1 Agonists activate phospholipase C and a-2 agonists inhibit 
adenylate cyclase and the formation of cyclic adenosine monophosphate (cAMP).
All p-agonists act by the same mechanism and activate adenylate cyclase to 
stimulate the production of cAMP. Even though all the p receptors produce the 
same secondary messenger (cAMP) each type of receptor produces a different 
response. P-l Receptors increase cardiac rate and force, relax gastrointestinal tract 
smooth muscle and are found mainly in heart muscle, p-3 Receptors encourage 
lipolysis and are associated with fat cells, p-2 Receptors cause bronchodilation, 
vasodilatation, relaxation of visceral smooth muscle, hepatic glycolysis and muscle 
tremor. It has not yet been possible to produce a P-agonist which only stimulates 
one specific receptor type. p-Agonists are allocated to a group by their relative 
strength of action rather than by a specific individual action. Like
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anabolic/androgenic steroids, compounds have been developed which maximise the 
desired effects and minimise, but not eliminate, the undesired effects.
As indicated above, all P-agonists stimulate the production of cAMP. Figure 
2.12 illustrates the mechanism of action. All adrenoceptors are G proteins. The 
term G protein simply means that the receptor interacts with the nucleotides 
guanidine triphosphate (GTP) and guanidine diphosphate (GDP). When the receptor 
is in its normal resting state, the G-protein exists as a trimer of a, P and y subunits 
with GDP bound to the a  subunit. When a receptor is activated by binding to an 
agonist, the receptor combines with the a  subunit and a molecule of GTP exchanges 
with the GDP. The GTP allows the a  subunit to dissociate itself from the other two 
units and bind to the target enzyme, in this case adenylate cyclase, and allows the 
formation of the secondary messenger. The GTP is then hydrolysed to GDP by the 
a-subunit and this then re-associates with the other two units of the trimer. The 
system then reverts to the resting state.
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Resting
state
Receptor
occupied
Receptor Receptor
GTP 
hydrolysed
Target
protein
activated,
Receptor Receptor
Figure 2.12 Mode of action of Beta agonists
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Chapter 3 Analytical Techniques
While it is possible to analyse biological matrices directly for some 
compounds of interest, for example headspace analysis for volatile components, it is 
more usual that some form of sample pre-treatment is required for an effective and 
sensitive analysis. In this study the majority of the analyses were accomplished 
using either liquid-liquid or solid phase extraction (SPE) pre-treatment prior to 
analysis by gas chromatography (GC) or gas chromatography-mass spectrometry 
(GC-MS). A discussion of the principles of these techniques is given below.
Chromatography Theory.
When a compound is subjected to a chromatographic process, it is
partitioned between the mobile phase and the stationary phase. The distribution 
between these two phases can be expressed by the distribution constant ( KD) which 
is defined as the ratio of the weight of solute in equal volumes of stationary and 
mobile phase:
_  Concentration per unit volume o f  stationary phase cs 
D Concentration per unit volume o f  mobile phase cm
As it passes along a chromatographic column, all compounds spend exactly 
the same amount of time in the mobile phase. The separation is caused by the 
compounds spending different amounts of time in the stationary phase.
The amount of time a component spends in the mobile phase can be 
determined by introducing into the system an unretained component. In gas
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chromatography, for example, methane is commonly used. The total retention time 
on the stationary phase can be expressed as
tr '= tr ~ tmt  t  m
where tr' is the stationary phase retention time or adjusted retention time, 
tm is the retention time of an unretained component, and tr is the time between 
injection and detection.
For a chromatographic process to be as sensitive as possible, it must deliver 
the solutes to the detector in as short as time as possible between the first and last 
molecule leaving the column. Thus the retention time on the column for all 
molecules of one particular compound is as similar as possible. The longer a 
compound spends on a column, i.e. the greater in KD, the wider the band of solute 
becomes. This band widening can be influenced by many factors, including 
longitudinal diffusion.
The separation efficiency of a column is related to the extent to which a 
solvent band widens or lengthens relative to the retention time on the column and is 
measured in theoretical plates, a term taken from distillation technology. The 
number of theoretical plates (n) is defined as:
where 8  is the standard deviation of the peak.
To ease calculations, if it is assumed that the peak is Gaussian, this equation 
can be rearranged as:
Page 48
or
n =  16
n = 5.54
where wb is the peak width at the base and wh is the peak width at half the
height of the peak. These assumptions can be made because peak width at the base 
of a peak is 4 8  and at half height is 2.354 8 . In practice, the calculation of 
theoretical plates is normally carried out using the peak width at half height, as it is 
normally easier to determine this value. If the adjusted retention time, t r',  is used 
in the equations the value obtained is called the number of effective theoretical 
plates, N.
Column efficiency can also be expressed as the height equivalent to a 
theoretical plate, h, and is calculated by>
n
where L is the length of the column. Likewise, the height equivalent to an effective 
theoretical plate, H, is a calculated by substituting in N  for n in the previous 
equation. The greater the column efficiency, the smaller the values of h and H. N, 
n, h and H are all affected by the column temperature, column geometry, the nature 
of both the mobile and stationary phases, and the nature of the test compound.
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As stated above, all compounds spend the same amount of time in the 
mobile phase, ( tm), but varying amounts of time in the stationary phase, tr '. The 
partition ratio (or capacity factor), k, is defined as the amount of a solute in the 
stationary phase compared to the amount of solute in the mobile phase. This 
relationship is proportional to the amount of time a solute spends in the stationary 
phase ( t r' ) relative to the amount of time the solute spends in the mobile phase, tm, 
and this can be expressed as:
It is possible to calculate the difference between the theoretical plate number 
(n) and the effective theoretical plate number (N). This difference is a function of k 
and can be expressed by:
As the retention time increases, i.e. a large value of k, the value of N  
approaches n.
It should be apparent that k is related to KD. This relationship depends on 
the relative availability of both the mobile phase and the stationary phase, i.e. the 
volumes of each component of the chromatographic system. This is called the 
column phase ratio and is given the symbol /5
If the equation for the distribution constant KD is rearranged it can be expressed as
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Amount in the stationary phase / volume o f the stationary phase 
Amount in the mobile phase / volume o f the mobile phase
If this equation is multiplied out, the following is obtained
Amount in the stationary phase Volume o f the mobile phase
rCp 1 " X
Amount in the mobile phase Volume o f the Stationary phase
The second part of the equation is the column phase ratio, (3, and the initial 
part of the equation is the partition ratio, k. Therefore,
k d = p  k
Separation of two components in a chromatographic system
The ability of a chromatographic system to separate two components is 
termed resolution and is given the symbol Rs . This ability to separate peaks 
depends on the ratio of the retention times of the two components and the sharpness 
of the two peaks and is given the symbol a. This value a  is expressed as:
t.r(2)
a  =  — —
(r( 1)
Consequently, it can be seen that
k K
a  _  (2 ) _  D(2)
k K *(1) £^>(1)
As the value of a  decreases, so greater and greater numbers of theoretical 
plates are required to achieve separation.
The resolution of two peaks can be calculated from:
2 ( / r ( 2) “RS=;
W H l ) + W b(2)
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If the peaks are assume to be Gaussian, then the relationship between wb 
and wh can be used to the equation can be stated as:
l-18(/r(2)- r^(1))
Rs = --------------------
WHl) +Wh( 2)
A resolution of 1.5 is required to provide base line separation of two 
Gaussian peaks. In practice, a greater degree of resolution is required to provide 
base line separation, as other chromatographic factors come into play, e.g. peak 
tailing and asymmetry
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Mass Spectrometry.
The mass spectrometer is used to give measurements of isotopic masses and 
abundances. Early work by J J Thompson74 demonstrated the isotope forms of 
stable isotopes. There are several types of mass analyser available, two of which 
were used in this study.
A pre-requisite for analysis by mass spectrometry is the formation of ions. 
There are several means by which ions can be formed but the most common method 
is by using the electron impact source. The majority of work in this study was 
carried out using electron impact ionisation. This source was initially employed by 
Dempster74 and further developed by Nier74. A schematic diagram of the electron 
impact source is shown in Figure 3.1. The sample, in the form of a vapour, passes 
through an electron beam. The electrons, formed by heating a filament (normally 
made of tungsten), are accelerated towards the electron trap. Some of the electrons 
pass through an opening in this plate into a chamber containing the vaporised 
sample. The gaseous sample molecules interact with the electrons and some of the 
molecules lose an electron to form positive ions. These ions may then further *break 
up' or fragment. Approximately 0.1 % of the sample molecules become ionised. 
These positively charged ions are repelled or expelled from the ion source by 
applying a small voltage to the repeller plate. The actual ionisation chamber is 
relatively gas tight to aid the ionisation of the sample molecules but the source 
housing and the analyser sections of the mass spectrometer must be kept under a 
high vacuum to prolong the life of the filament and the stability of the ions formed 
in the electron source. All areas of the electron source are kept heated to prevent the 
condensation of the sample vapour on the source.
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Ions
Sample entry
Source
magnets
Filament TrapRepel ler
Figure 3.1 Schematic Diagram of an Electron Impact Source.
The ions are then analysed by their mass to charge ratio. As stated above, 
there are several types of mass analyser available. The modes of operation of the 
two types of analyser used in this study were:
1) Magnetic Sector Analyser. (Figure 3.2a)
In this type on analyser, the ions, after exiting from the source come under 
the influence of the accelerating plates. These plates can be held at up to 10,000 
volts and their purpose is to increase the kinetic energy of the ions. The kinetic 
energy gained by the ions is the same as the potential energy lost and can be 
summarised by>
zeV = Equation 1
where e is the charge on an electron, z is the number of the charges on the 
ion, m is the mass of the ion, V is the applied voltage and v is the velocity of the ion. 
For the ion to reach the detector successfully, it must traverse a curved path of 
radius of curvature r, through a field of magnetic strength B. Equation 2 expresses 
the balance between the angular momentum and the centrifugal force caused by the 
magnetic field:
mv2 = Bzev Equation 2
r
If the second equation is re-arranged it can be seen that:
mv
—  = Bze Equation 3 
r
mv is also known as momentum so it can be seen that a single magnetic sector 
instrument is in reality a momentum analyser.
If equations 1 and 2 are combined, the basic mass spectrometry equation is 
obtained
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Figure 3.2 Various Types of Mass Spectrometers
m B r e
— = Equation 4z 2V
By varying the magnetic field strength (B) or the voltage (V) ions of different 
m/z ratio can reach the detector.
2) Double Focusing Mass Spectrometer. (Figure 3.2b)
The resolution of a mass spectrometer can be defined as its ability to 
separate ions of adjacent mass numbers. The resolution necessary to separate two 
masses is described in equation 5 and illustrated in Figure 3.3:
R = Equation 5
Am
where R is the resolution, m is the mass of an ion and Am is the difference in 
mass between the two ions. Resolution in mass spectrometry is comparable to 
resolution in chromatography, the closer two peaks are together, the greater the 
resolution required to baseline separation. Two peaks of equal intensity are 
considered to be separated by a valley of 10% of the height of either peak. At this 
point, the 10% valley consists of a contribution of 5% from each peak.
The higher the resolution, the greater the ability of a mass spectrometer to 
distinguish between two masses. A resolution of 580 is required to separate argon 
molecular weight 39.96239 from C3H4, molecular weight 40.03130. A resolution of
13 12
20 600 is required to distinguish between C C6H? xylene fragment ion weight 
92.05813, and toluene C ^ ,  molecular weight 92.06260.
Page 57
As stated above, a magnetic sector instrument is effectively a momentum 
analyser. If two ions have the same mass but a different translocational energy, they 
will not be brought to a focus at the same point on the detector. The spread of this 
translocational energy limits the resolution of the instrument. This limitation can 
be overcome by the introduction of an electrostatic sector to the instrument.
An ion entering the electrostatic field travels along a path of radius r such 
that the electrostatic force balances the centrifugal force. The equation of motion is
mv2
 = ezE Equation 6
r
where E is the electrostatic field strength. Thus the radius of curvature of 
the ion is dependent on the energy of the ion, not the mass.
3. Quadrupole Mass Analysers (Figure 3.2c)
As the name suggests, a quadrupole analyser consists of four parallel rods of 
circular or hyperbolic cross section arranged symmetrically around a central axis. 
The rods lying opposite each other are coupled. The ions leave the source and drift 
down between the rods. By applying a combination of radio frequency and direct 
current to the rods, a mass separation occurs. For any one particular frequency, ions 
of a particular mass to charge ratio (m/z) will pass through the analyser and 
successfully reach the detector. Ions lighter than this particular mass will tend to 
strike the positive poles and heavier ones will strike the negative poles. Quadrupole
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mass analysers have the advantage that they can be significantly cheaper than sector 
instruments, but suffer from the lack of resolution.
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Figure 3.3 Definitions of Resolution
Interfacing a Mass Spectrometer and a Gas Chromatograph.
For a mass spectrometer to work efficiently, it must be kept under the best 
vacuum possible. When interfaced to a gas chromatograph, this aim is 
compromised. The gas chromatograph actively puts molecules in the gaseous phase 
into the mass spectrometer. Depending on the nature of the column in the gas 
chromatograph and the flow rate of the carrier gas through the column, there are a 
variety of methods of sample introduction to a mass spectrometer, two of which are 
detailed below.
1. The Jet Separator.
If the column employed is a packed column or a capillary column with a
relatively high flow rate (greater the 5ml/min) the pressure in the ion source and 
source housing is liable to be too high for efficient mass spectrometry. The jet 
separator is used to enrich the sample by removing as much of the carrier gas as 
possible while leaving the largest possible amount of the sample. The jet separator 
is such an enrichment device and was developed initially by Ryhage. For a detailed 
description of the jet separator see Chapman 74 This technology is little used 
currently. The use of capillary columns has allowed a second route of sample 
introduction from a gas chromatograph.
2.) Direct Coupling.
If the chromatographic column has a low flow rate, normally a capillary
column of internal diameter less the 0.32 mm and a flow rate below 3ml/min, it is 
possible to directly couple the column to the mass spectrometer. The high pumping 
speeds of modem pumps can remove the carrier gas efficiently enough to maintain a
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good vacuum and prevent significant interferences from any residual carrier gas. In 
direct coupling, the column can terminate only a few millimetres from the electron 
beam and so deliver almost all the sample to the ion source, increasing sensitivity of 
the analysis. The area between where the column leaves the gas chromatograph and 
enters the mass spectrometer is termed the transfer line. This transfer line must be 
kept hot. If not, material will condense out in the transfer line and efficient transfer 
of the analyses between the gas chromatograph and the mass spectrometer will not 
occur.
Extraction Techniques
As indicated above, it is not normally possible to analyse samples directly. 
Compounds of interest must usually be extracted from the matrix that they are in. 
This allows the sample to be concentrated and many components in the matrix to be 
removed which could interfere in the analysis. Two types of extraction procedure 
were used in this project.
1). Liquid-Liquid Extraction.
This is the traditional type of extraction where an aqueous sample is agitated
with an immiscible organic phase, (e.g. ethyl acetate) and the compounds of interest 
leave the aqueous phase and enters the organic phase. At equilibrium, the ratio of 
compounds between the two phases is constant and this gives a number, called the 
distribution constant, Kd and is defined as follows;
where Kd is the distribution constant, cx is the amount in the organic phase and c2 
is the amount in the aqueous phase.
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This constant can be dependent on concentration but this only comes into 
play if the level of material is greater than 0.1M. In order to hasten the attainment 
of equilibrium, the samples are normally agitated. If the samples are of low 
viscosity (e.g. water) and low volume (less than 100 ml) it has been shown that in 
test tubes as little as 50 shakes are necessary for the attainment of equilibrium. It is 
normal practice to leave the samples on a shaking platform of some form for around 
10-15 minutes to ensure the attainment of equilibrium. It is also possible to 
manipulate the conditions in the aqueous phase to increase the selectivity of the 
extraction by the use of buffers and ion pairing reagents. Once this equilibrium has 
been established, the two layers are separated and the layer of interest is kept and 
subjected to either further manipulation or analysis.
2. Solid Phase or Sorbent Extraction.
Sorbent extraction is a physical extraction process that involves both a solid
and liquid phase. A liquid sample is passed over the sorbent bed, which binds the 
compounds of interest reversibly. Once bound, interfering substances can be eluted 
from the sorbent bed by the use of carefully selected washes. These washes can be 
aqueous, organic or mixtures of aqueous and organic solvents. Once the majority of 
the interferences have been removed, the compounds of interest can be eluted form 
the sorbent bed by the use of an appropriate solvent. In general, the sorbent consists 
of functional groups attached to a chemically modified silica backbone. A wide 
variety of functional groups is available. One of the more common functional 
groups is C l8, an octadecyl straight chain hydrocarbon. It extracts the compounds 
of interest from the biological matrix primarily by non-polar interactions. It is the 
most non-polar sorbent available and is probably the least selective sorbent. It
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retains almost anything from an aqueous mixture. Polar and cation exchange 
mechanisms are also possible on a C l8 column, the cation exchange properties 
arising from the activity of silanol groups within the silica backbone. The ‘Sorbent 
Extraction Technology Handbook’ provides a detailed review of the principles of 
sorbent or solid phase extraction, and the various functional groups available75.
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Chapter 4 Analytical Techniques Practical
This section details common analytical procedures employed in these 
studies. Additional relevant methodology is listed in each of the following sections 
as appropriate.
Materials
Steroid standards, deuterium-labelled testosterone standard, Helix pomatia 
digestive juice, creatinine assay kits, clenbuterol hydrochloride and 
heptafluorobutyric acid anhydride were purchased from Sigma Chemicals Ltd., 
Poole, Dorset, UK. ^H-Testosterone (specific activity 319mCi/mg) was purchased 
from Amersham International pic, UK. ^H-Corticosterone, ^H- 
dehydroepiandrosterone sulphate and ^H-oestradiol glucuronide were purchased 
from New England Nuclear, USA. Methoxyamine hydrochloride, 
trimethylsilylimidazole (TMSI) N-methyl-N-(trimethylsilyl)-trifluoroacetamide 
(MSTFA) and hexamethyldisilazane (HMDS) were purchased from Pierce 
Warrender, Chester, UK. Insta-gel scintillation fluid and Lipidex-5000 were 
purchased from Canberra Packard Ltd., UK. Laurabolin (nandrolone laurate) was 
obtained from Intervet UK Ltd, Cambridge, UK. All other solvents and reagents 
employed were of analytical grade or higher.
Gas Chromatography-Mass Spectrometry System 1.
The gas chromatograph was a Hewlett-Packard model HP5890 fitted with a 
fused silica column (CP-Sil 5 ,25m x 0.32mm i.d., df 0.4 pm). Samples were 
injected using a Hewlett-Packard model 7673 autoinjector and a split/splitless 
injector fitted with a goosenecked liner. The latter was operated in the splitless 
mode for 0.7min after injection. The mass spectrometer used was a VG Analytical 
model 70-250S double focusing instrument. The delivery line from the GC to the
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MS was held at 280°C. The carrier gas employed was helium with a linear velocity 
of 30cm/sec. Individual gas chromatograph and mass spectrometer parameters are 
listed with the appropriate section.
Gas Chromatography-Mass Spectrometry System 2.
System 2 consisted of a Carlo Erba Gas Chromatograph model GC8000 
containing a DB-5-MS fused silica column (20m x 0.18mm, df 0.18 pm) attached to 
a Fisons Instruments MD800 quadrupole mass spectrometer. The carrier gas used 
was helium, with a linear velocity of 25cm/second. The injector temperature was 
held at 250°C. The delivery line between the gas chromatograph and the mass 
spectrometer was held at 270°C. All samples were injected using an AS800 
autosampler with the gas chromatograph operating in the splitless mode for one 
minute after injection. For the relevant mass spectrometer and gas chromatograph 
parameters, see the appropriate text.
Scintillation Counting
All scintillation counting used a Canberra Packard 2200CA Tri-Carb liquid 
scintillation analyser. All samples were counted for five minutes.
Extraction of Urinary Steroids to Establish the Typical Urinary Steroid Profile 
of the Racing Greyhound
The following method was used, based on procedures published by 
Shackleton et al.76’77,78.
Extraction and Hydrolysis
Urine (10ml) was centrifuged at 2500 rpm for 10 minutes to remove any 
particulate material. The urine was applied to a C l8 Sep-Pak® cartridge which had 
been conditioned with methanol (10ml) and distilled water (10ml). The cartridge 
was washed with a further portion of distilled water (10ml) and eluted with
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methanol (5ml). The extract was taken to dryness under a stream of nitrogen at 
60°C. Once dry, the residue was suspended in sodium acetate buffer (pH 4.6, 0.2M, 
20 ml) and Helix pomatia digestive juice extract containing approximately 100,000 
units of glucuronidase activity and 8,000 units of sulphatase activity was added.
This was incubated in a water bath at 55°C for 3 hours or at 37°C for 24 hours.
Following incubation, the sample was re-extracted through the same C l8 
Sep-Pak® cartridge previously used following the same procedure described above. 
The extract was taken to dryness under a stream of nitrogen at 60°C and the residue 
was dissolved in cyclohexane:ethanol (4:1 v/v, 5ml).
Sample Purification
Sephadex LH-20 (lg) was equilibrated in an excess of cyclohexane:ethanol 
(4:1 v/v). Once equilibrated, the gel was transferred to a chromatography column 
(20cm x 1cm i.d.) with a reservoir (50ml) at the top and a sintered glass plate above 
a stopcock at the lower end. The sample was loaded onto the Sephadex column, 
taking care not to allow the Sephadex to dry out. The column was eluted with a 
further portion of cyclohexane:methanol (4:1 v/v, 45ml). This fraction contained the 
steroids while the more polar components of the matrix were retained on the 
column. The column was regenerated by washing with methanol (75ml) before re­
conditioning it with cyclohexane:ethanol (4:1 v/v) prior to loading the next sample.
The fractions containing the eluted steroids were concentrated by rotary 
evaporation, transferred to vials and stored at -20°C until required for analysis.
Formation of Methoxime Derivatives
Each extract was dried under a stream of nitrogen and a solution of 
methoxyamine hydrochloride (2% w/v in pyridine, 50ml) was added and incubated 
at 60°C for 60 min.
Formation of Trimethylsilyl Derivatives
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TMSI (50ml) was added and the mixture heated for 16 hours at 100°C.
Removal of Excess Derivatisation Reagents
To remove the excess derivatisation reagents the mixture was passed through 
a short column of Lipidex-5000 equilibrated with cyclohexane:pyridine:HMDS 
(98:1:1, v/v/v). Once the sample was applied, the column was eluted with a further 
portion of cyclohexane:pyridine:HMDS (2ml). This fraction was collected and 
evaporated under a stream of nitrogen at 60°C and the residue re-dissolved in 
hexane (lOOpl) and aliquots (1 pi) analysed by GC-MS.
GC-MS Conditions
All GC-MS was carried out employing system 1. The injector temperature 
was 280°C and the column oven was programmed from 60°C, (held for 0.5 min), at 
20°C/min to 200°C, (held for 0.5min), then at 5°C/min to 300°C (held for 15 min). 
The MS was operated in full scan mode (1 second/decade, interscan time 0.3sec) 
using electron impact ionisation at 30eV.
Metabolic Study 1: ^H-Testosterone 
Dose Preparation
Radioactive testosterone (ca 150 mCi) was dissolved in 60% aqueous 
ethanol. The dose homogeneity was checked by taking small known aliquots of the 
dose and assessing the radioactivity present. The coefficient of variance (c.v.) was 
determined and found to be acceptable (c.v.=0.87%, n=6). The dose was sterilised 
by passing it through a Millix-OR 0.2mm filter obtained from Millipore, and sealed 
in a sterile vial with a rubber septum.
Dose Administration
One male greyhound was dosed intravenously with 1 ml of the prepared 
solution, injected into the jugular vein. The greyhound was housed in a steel
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metabolic cage to allow complete collections of urine and faeces to be made, and to 
prevent the radioactive contamination of the kennel environment.
Sample Collection
To facilitate the collection of blood samples, a cannula was inserted into the 
jugular vein of the animal under local anaesthetic prior to dosing. Blood samples 
were collected by allowing blood to pass through the cannula into the heparinised 
sample tubes and were separated into red blood cells and plasma by centrifugation. 
The plasma was removed for analysis. Separate urine collections were made at 8h, 
24h, 48h, 72h and 120h post dose into pre-weighed containers. Faeces were 
collected when possible.
Sample Analysis
Portions of the plasma were taken and made up to 1ml where necessary with 
water. Scintillant, (Insta-gel, 10ml) was added and the mixture shaken. The 
radioactivity present was determined by scintillation counting for 5 min. The total 
weight of urine excreted was determined. A portion of the sample (ca. lg) was 
weighed into a scintillation vial and scintillant (Insta-gel, 10ml) was added. The 
radioactivity present was determined by scintillation counting for 5 min.
2
Metabolic Study 2: H3-Testosterone
Dose Preparation
2
H3-testosterone (8 mg) was dissolved in 60% aqueous ethanol. The 
solution was filtered through a Millix-OR 0.2mm filter, and transferred to a sterile 
vial which was then sealed with a sterile rubber septum.
Dose Administration
One male greyhound, the same animal used for the radiolabelled testosterone 
experiment, was dosed intravenously with 1 ml of the prepared solution, injected 
into the jugular vein.
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Sample Collection
Blood samples were taken from the jugular vein by syringe and transferred to 
heparinised blood tubes for separation into red blood cells and plasma. Urine 
samples were collected by a kennel nurse in a bowl during exercise periods.
Sample Analysis
This extraction method is based on a procedure by Belanger et al.79.
Ethanol (5ml) was added to the plasma sample (1ml) and gently mixed for 5 
minutes. The sample was centrifuged (2500 rpm, 5min.) and the supernatant 
removed. The pellet was washed with a further portion of ethanol (5ml), 
centrifuged and the supernatant was removed and combined with the supernatant 
already obtained. The combined extracts were taken to dryness under a stream of 
nitrogen at 60°C. To each sample, internal standard, 17p-trenbolone was added.
The dry residue was suspended in methanol:water (5:95 v/v, 2ml, solution A). A 
C l8 Sep-Pak® cartridge was conditioned with methanol (10ml), distilled water 
(10ml) and solution A (10ml). The sample was loaded onto the column and washed 
with solution A (10ml). The steroids were eluted from the column with 
methanol:water (85:15 v/v, 3.5ml,).
Sample Derivatisation
The extract from the Sep-Pak® cartridge was taken to dryness under a 
stream of nitrogen at 60°C. Trimethylsilyl derivatives were formed by adding 
MSTFA (50pi) and incubating at 60°C for 15 min.
Gas Chromatography Parameters
All GC-MS work was carried out using GC-MS system 1. The injector 
temperature was 280°C. The column oven was programmed from 100°C, (held for 
0.5 min), at 10°C/min to 300°C (held for 15 min). Aliquots (lpl) were injected
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using a Hewlett-Packard model 7673 autoinjector.
Mass Spectrometry Parameters
The ions monitored and the dwell times are listed in Table 4.1. The ratio of
2 2
H3-testosterone to HQ-testosterone was calculated from the relative areas under
2 2 
selected ion chromatograms for their molecular ions of ^-testosterone and HQ-
testosterone.
Metabolic Study 3: Nandrolone (19-nortestosterone)
Dosing
Two dogs were dosed intramuscularly with 1ml of Laurabolin, a commercial 
preparation containing 50mg of nandrolone laurate per ml of oily solution.
Sample Collection
Blood samples (approximately 10 ml) were collected in heparinised sample 
tubes from either the jugular vein or the saphenous vein both pre-dose and at known 
time intervals post dose. Plasma was obtained by centrifuging the collected blood 
samples at 2500 rpm for 10 minutes. Urine samples were collected as and when 
produced by the greyhound. All samples were stored at -20°C until required for 
analysis.
Sample Extraction
2
Plasma samples were extracted as for the ^-testosterone samples using
2
H3-testosterone as the internal standard.
Urine samples were extracted using Bond-Elut® C l8 cartridges containing
2
500 mg of sorbent. Following the addition of H3-testosterone as an internal 
standard, the urine sample (10ml) was loaded on a cartridge which had been 
conditioned with methanol (5ml), water (5ml) and methanol:water (5:95 v/v, 5ml). 
After loading the sample, the cartridge was washed with methanol:water (5:95 v/v,
Page 71
5ml) and eluted with methanol:water (80:20 v/v, 5ml). This extract was taken to 
dryness under a stream of nitrogen at 60°C and re-dissolved in sodium acetate buffer 
(pH 4.6, 0.2M, 20 ml). Helixpomatia digestive juice extract containing 
approximately 100,000 units of glucuronidase activity and 8,000 units of sulphatase 
activity was added and the mixture was incubated in a water bath at 37°C for 16 
hours. The samples were then re-extracted through the Cl 8 cartridges used 
previously using the same methodology.
Sample Derivatisation
Sample derivatisation was based on a method published by Ehrsson et a l80. 
The extracts obtained were taken to dryness under a stream of nitrogen at 60°C and 
dissolved in toluene (0.5ml). Triethylamine (0.05M in toluene, 100pi) and 
heptafluorobutyric acid anhydride (100pi) were added and the resulting mixture 
heated at 100°C for 15 minutes. Following incubation, the solvent was removed 
under a stream of nitrogen at 60°C and the residue re-dissolved in toluene (100pi), 
prior to analysis GC-MS.
GC-MS Parameters
2
The gas chromatography parameters employed were the same as for H3- 
testosterone. The mass spectrometer was employed in the selected ion recording 
mode, monitoring the ions listed in Table 4.2.
Creatinine Measurements
The levels of creatinine in each urine sample were determined with a 
commercial kit according to the manufacturer's instructions, using a suitable dilution 
of the urine81.
The diluted urine sample, blank or standard (0.3ml) was added to a plastic cuvette 
along with the supplied alkaline picrate solution (3ml) and allowed to stand at room 
temperature for 10 minutes. The absorbance of the standard and blank solutions
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were measured against the blank at 500nm. Acid reagent (0.1ml) was added to each 
cuvette, mixed thoroughly and allowed to stand for five minutes. A second reading 
of each sample was taken. The concentration of creatinine in each samples was 
determined using the following formula:
Initial A , -  Final At„f
 ----- - f - — - — - f -  * Std Cone
Initial Astd -  Final Asid
where Atest is the absorbance of the urine sample, Astd is the absorbance of 
the standard creatinine solution and Std Cone is the concentration of the standard. 
The correction factor for diluting the urine must also be applied. In general a thirty 
fold dilution of the greyhound urine sample was required (for humans, the kit 
recommends a 10 fold dilution). Results were expressed as mg/ml. The assay was 
specified to be accurate up to lOOmg/litre.
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Metabolic Study 4: Boldenone (1,2-dehydrotestosterone)
Dosing
Two dogs were dosed intramuscularly with 1ml of Venobol, a commercial 
preparation containing 25 mg of boldenone undecylenate per ml of oily solution. 
Sample collection was as for the ^Ry-testosterone experiment except that the 
samples were taken from the saphenous vein.
Sample Extraction
2
Plasma samples were extracted as for the H3-testosterone samples using
2
H3-testosterone as the internal standard.
Urine samples were extracted as for nandrolone
Sample Derivatisation
The extract from the Sep-Pak® cartridge was taken to dryness under a 
stream of nitrogen at 60°C. Trimethylsilyl derivatives were formed by adding 
MSTFA (50 pi) and incubating at 60°C for 15 min.
GC-MS Parameters
All GC-MS work was carried out using GC-MS system 1. The gas2
chromatography parameters employed were the same as for H3-testosterone. The 
mass spectrometer was employed in the selected ion recording mode, monitoring the 
ions listed in Table 4.3.
Creatinine Measurements
As for nandrolone.
Metabolic Study 5 Clenbuterol
Dose Preparation and Dosing
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A known weight of clenbuterol (approximately 2 mg free base) was 
dispensed into a hard gelatine capsule and the remainder of the volume of the 
capsule was filled with lactose. One capsule was administered to one dog and one 
bitch by placing the capsule in the mouth of the greyhound and holding the 
greyhounds muzzle until the capsule was swallowed.
Sample Collection.
As for the studies with nandrolone.
Sample Extraction
A liquid-liquid extraction technique based on previously published 
methodology was used8. Plasma or urine samples (1 ml or 2 ml respectively) and 
internal standard (salbutamol) were placed in a test tube with sodium hydroxide 
buffered at pH 12 with sodium hydrogen carbonate (2M, 1ml). Ethyl acetate (6ml) 
was added and the samples were placed on a rock and roll table for 15 minutes. The 
upper layer was decanted and the ethyl acetate extraction repeated. The combined 
ethyl acetate layers were back extracted into sulphuric acid (0.2M, 1 ml) for 10 
minutes. After centrifugation (2000g, 10 min) the upper layers were discarded. 
Ethyl acetate/hexane (2:1,4 ml) was added and the acid layer was extracted for 5 
minutes. The organic layer was discarded. Sodium hydroxide (2M, 1ml) was added 
to make the extract alkaline and ethyl acetate (4ml) was added and the samples 
extracted for 15 minutes. The upper organic layer was transferred to a clean 3ml 
vial and stored at 4°C until required for analysis.
Sample Derivatisation
The extracts were taken to dryness at 60°C under nitrogen and BSTFA with
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1% TMCS (50|il) was added. The samples were incubated at 80°C for 30 minutes 
prior to analysis as described below.
Creatinine Measurements
As for nandrolone.
GC-MS Parameters
GC-MS System 2 was used for the analysis of the biological extracts. The 
injector temperature was 250°C and the column oven was programmed from 100°C 
(held for 1 minute) at 10°C per minute to 300°C (held for 5 minutes). The delivery 
line between the Gas chromatograph and the mass spectrometer was held at 270°C. 
The instrument was operated in the selected ion monitoring mode and the ions 
monitored are listed in Table 4.4.
Page 76
Compound Ions (m/z) Dwell time (ms)
17P-Trenbolone 327.1780 5
342.2015 5
2Ho-Testosterone 345.2250 50
360.2485 50
2H3 -T estosterone 348.2438 50
363.2673 50
Table 4.1: Selected ion recording parameters used for the analysis 
of selected steroids as their trimethylsilyl derivatives.
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Compound Ions (m/z) Dwell time (ms)
Testosterone/ 665.1373 50
Epitestosterone 680.1608 50
Nandrolone 666.1451 50
2H3 -Testosterone 668.1561 10
683.1795 10
Etiocholanolone/ 471.1770 50
Androsterone 486.2005 50
Table 4.2: Selected ion recording parameters used for the analysis 
of selected steroids as their heptafluorobutyrate derivatives.
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Compound Ions (m/z) Dwell time (ms)
Testosterone/ 345.2250 50
Epitestosterone 360.2485 50
Boldenone 50
2 H3 -T estosterone 348.2438 10
363.2673 10
Table 4.3: Selected ion recording parameters used for the analysis 
of selected steroids as their trimethylsilyl derivatives.
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Compound Ions Dwell Time (ms)
Clenbuterol 86.10 50
262.03 50
264.02 50
Salbutamol (Internal 86.10 50
Standard) 369.17 50
Table 4.4: Selected Ion Recording Parameters used for the Analysis 
of Clenbuterol and Salbutamol as their Trimethylsilyl Derivatives
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Chanter 5 Elucidation of Endogenous Steroid Biochemistry
of the Racing Greyhound
Introduction
The detection of exogenous steroids in the greyhound or the detection of 
administration of steroids which are normally present in the greyhound both require 
background knowledge of greyhound steroid biochemistry. The reasons for this are 
almost self-evident but can be summarised as follows:
The steroid profile in biological specimens in most mammals is complex and likely 
to result in interferences in analyses targeting either endogenous or exogenous 
steroids. In addition, the steroid profile is related to the action of steroidal 
hormones and is therefore periodic or variable over several time-scales, both 
geophysical and biological within individual animals. Superimposed on this is inter- 
individual variation
While the detection of exogenous substances may be easier and less ambiguously 
interpreted, the detection of supplementary endogenous hormones usually requires a 
different approach based on changes caused to the endogenous steroid profile 
resulting from the administration of the steroids. In humans, for example, 
administration of testosterone and its esters may be detected by changes induced in 
the testosterone:epi-testosterone ratio. The International Olympic Committee have 
adopted a threshold ratio of 6:1 as an indication of administration of testosterone. 
However, this has been subject to legal challenge in recent years, following the 
detection of individuals who apparently have normal ratios above this threshold.
For these reasons, and also, because little has been published concerning steroids in 
the greyhound, it was considered essential to examine the normal steroid pattern in 
greyhounds before beginning controlled metabolic studies of administered 
substances.
The approach adopted drew on knowledge of the steroidal profile of other species, 
especially the human steroid profile, which has been extensively studied.
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Steroid Standards
Prior to the examination of the natural profile of steroids in greyhounds, a large 
number of pure steroid standards were derivatised to form both their trimethylsilyl 
(TMS) and methoxyamine-trimethylsilyl (MO-TMS) derivatives. The details of the 
derivatisation protocols and gas chromatograph-mass spectrometry parameters are 
given in Chapter 4. A list of some of the standards analysed along with the 
corresponding Kovats Indices are given in Table 5.1. These steroids included 
estrogens, androgens, progestagens and corticosteroids. Each sample was 
chromatographed three times and the quoted Kovats Index is the average of the 
three separate runs. The endogenous steroids selected to make up the standard 
mixture were determined by identifying steroids already noted as being present in 
the urine of other species, mainly human.
Initially, the amount of time required for the preparation of the TMS derivatives was 
far less than the reported sixteen hours at 100°C. Some of the steroids, and in 
particular the corticosteroids, did not always derivatise effectively unless these 
reasonably aggressive conditions were used. This was probably due to steric 
hindrance around position 17 of the steroid nucleus.
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Steroid Retention Index Retention Index
TMS Derivative MO-TMS derivative
Allo-THB 2560 2494, 2525+
Allo-THF 2549, 2559, 2641,2667 2500, 2604+
5a-Androstan-3(3, 17P-diol 2634 *
5-Androstene-3p, 16a-diol-17-one 2705, 2729, 2779 2711,2715 +
Androstane 2055 *
5-Androstene-3P, 16a, 17a-triol 2397 *
Cholestane 2751 *
5P-Cholestan-3a-ol 2877 *
Corticosterone # 2838
Cortisol 2967, 2970+
a-Cortolone 2084 2940
Ethynodiol 2788 *
11-P-Hydroxyandrosterone 2038 2273
20-a-Hydroxypregnenolone 2771 *
11-Ketoaetiocholanolone # 2235, 2280, 2249A
17-a-Methyltestosterone # 2717
1 9-Norethisterone 2706 2705
Pregnandiol 2392 2755
5P-Pregnane-3a, 17a, 20a-triol 2480 *
5-Pregnene-3p, 17a, 20a-triol 2827 *
Proligestone 2827 2861,2869+
Secrosterone # 2849, 2869+
Stanozolol 2920 *
THB 2564 2486
THE 2902 2837
THF 2500 2541
Trenbolone 2766 2645
Notes
* Compound contains no carbonyl group. No methoxime derivative will therefor be formed.
# Inconclusive data See text for details
A Differing levels of derivitisation can occur. Enolisation may occur.
+ Two peaks resulting form syn and anti isomers of methoximes. See text for details
Table 5.1 Steroids and Kovats Indexes
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As well as the lack of formation of some of the derivatives described above, three 
other features were noted.
• The formation of two or more peaks. (Indicated by + in Table 5.1)
It was possible to form two or more derivatives for some of the compounds.
With the methoxime-TMS derivatives, this depends on the stereochemistry (syn- 
anti) of the compounds formed. Although problematic when trying to determine 
the complete steroid profile of the greyhound due to the creation of more peaks 
in the mass chromatogram, this ‘double peak’ formation can be utilised 
effectively. The ratio between the syn and anti isomers for a given compound 
and set of circumstances remains the same. In steroid analysis control by the 
Horseracing Forensic Laboratory, Newmarket, these two peaks are used as an
JOadditional check to confirm the identity of compounds. A compound will only 
be identified as being present if both the syn and anti isomers are different. This 
is a different approach to that of many International Olympic Committee 
Laboratories where an aggressive TMS derivatisation procedure results in the 
formation of enol TMS derivatives.
• The formation of two or more peaks following TMS derivitisation (Indicated by 
A in Table 5.1)
This results from the production of enol derivatives. The peaks at retention 
indices 2235 and 2280 correspond to bis-TMS derivatives while the peak at 
retention index 2249 results form the formation of a tris-TMS derivative.
Further discussion of enolisation follows later in this chapter.
• The problematic formation of some derivatives. (Indicated by # in Table 5.1) 
These derivatives should have been relatively easy to form with the temperatures 
and reaction time used. However, when it came to running these compounds on 
the GC-MS it was not possible to obtain retention time or mass spectra reliably 
from these compounds. It appeared as if these compounds would 
chromatograph acceptably initially, but within one or two runs, the ability to
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chromatograph these compounds disappeared. Changing the gas chromatograph 
injector liner to a clean one of the same type or different types, injector 
temperature, septum or chromatographic column were all attempted but none of 
these appeared to rectify the problem. Problems of this nature have been noted 
before83 but no satisfactory explanation had ever been determined. This 
problem may be instrument-specific as recently, two similar instruments from 
the same manufacturer have been compared and one has the ability to 
chromatograph the compounds while the other cannot.
Elucidation of the background steroid profile of the racing 
greyhound
Following determination of the behaviour of a large number of steroids, work 
progressed to the determination of the normal urinary steroid profile of the 
greyhound. The principal method utilised was the analytical approach detailed in 
Chapter 4 after the method by Shackelton et al. 16,11. Initial experiments on human 
urine demonstrated that this analytical approach could be used to elucidate a steroid 
profile form a normal healthy male. However, all attempts to use this protocol to 
elucidate a similar profile in the racing greyhound met with limited success. The 
‘normal’ profiles for the male and female racing greyhound are given in Figures 5.1 
and 5.2.
Male Racing Greyhound (Figure 5.1)
It was not possible to establish the presence of any steroids in the urine of the male 
racing greyhound with certainty. Additional work was carried out and this is 
detailed later in this chapter.
Female Racing Greyhound (figure 5.2)
Unlike the male, it was possible to identify clearly the presence of steroids in the 
urine. These were 17(3-oestradiol (peak A), cortisol (peak B), tetrahydrocortisol
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(peaks C and D) and 3a, 1 10, 17a, 2Oa-tetrahydro-5-0-pregnane (peak E). It is 
probable that some of the other peaks present in the chromatogram are also 
steroids but it was not possible to identify these peaks definitively. The two 
peaks for tetrahydrocortisol are due to the formation of diastereoisomers.
One of the few papers published on the steroid metabolism of greyhounds deals
70with the determination of corticosteroids in the plasma . These authors 
examined the plasma levels of corticosteroids in the beagle and the greyhound. 
They reported mean plasma levels of 25.4 and 18 ng/ml of corticosteroids in 
beagles and greyhounds respectively. There appeared to be no significant 
difference between male and female greyhounds, with levels of 16.3 and 19.6 
ng/ml respectively. This assay only determines total corticosteroids in the 
sample and does not attempt to identify specific compounds. As the plasma 
levels of the corticosteroids appear to be similar, it would seem likely that the 
urinary levels would be similar. As said above, however, there do appear to be 
significant differences between the sexes.
These steroid profiles were obtained by extraction of pooled urine samples. It is 
possible that for the female animal, the animal was about to go into oestrus and 
the presence of the steroids in the urine indicates this. In particular, 170- 
oestradiol is associated with the control of oestrus in females.
It has been said that ‘Humans are swimming in steroids, while other animals are 
not’84. It is possible that for some unknown physiological purpose, humans have 
a far greater amount of steroids present in their system than do animals.
Verification of the Analytical Protocol
Following the failure to establish a steroid profile, the analytical protocol was 
examined stage by stage to determine if it was suitable for the analysis of 
exogenously-administered steroids in the racing greyhound.
The extraction protocol was examined using radiolabelled steroids. Urine was 
separately spiked with one of three steroids: tritiated corticosterone, tritiated
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170-oestradiol glucuronide or tritiated dehydroepiandrosterone sulphate (DHEA 
sulphate) at an approximate concentration of 200 ng/millilitre and 100,000 dpm. 
The samples were taken through the entire extraction protocol detailed in 
Chapter 4 and the recoveries of the steroids are given in Table 5.2.
One free and two different conjugated steroids were used. Steroids of different 
types were used to represent all the target analytes. As can been seen from the 
table, the recoveries of all the steroids are greater than 56%. Although not ideal, 
these recoveries are acceptable for a non-specific assay and clearly demonstrate 
that, if other steroids behave in a similar manner, then it should be possible to 
detect them using full scan mass spectrometry if they are present in any 
significant quantities. Once the suitability of the extraction assay had been 
determined, the effectiveness of the hydrolysis stage was examined. A high 
performance liquid chromatography system to separate 170-oestradiol and 170- 
oestradiol glucuronides was developed and is described below.
Analytical Set-up
An LKB 2150 pump was attached to a Hypersil C18 column (5 pm particle size, 
250mm x 4.6 mm). Detection was achieved using a Waters 490-MS UV/visible 
detector operated at 284 nm and the output of the detector was recorded on a 
Venture RE54120 strip chart recorder. The mobile phase was optimised for the 
separation of the two components and was a methanol water mix (80:20, v/v). A 
typical chromatogram showing the separation between the two components is 
shown in figure 5.3.
170-Oestradiol glucuronide was spiked into hydrolysis buffer and incubated with 
enzyme as detailed in chapter 4. Following the incubation period proposed there 
was no 170-oestradiol present in the extract.
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All this evidence combined suggested that there were little or no identifiable 
steroids present in the urine of the racing greyhound
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Steroid Concentration Mean % 
recovery
Upper
recovery
Lower
recovery
Standard
Deviation
Coefficient 
of variation
Number of 
samples
173-Oestradiol 200 ng/ml 
glucuronide
76.6 81.6 72.9 3.96 5.1 6
Corticosterone 200 ng/ml 63.7 77.2 50.6 9.3 14.6 6
DHEA
sulphate
200 ng/ml 56.5 68.3 44 9 16.4 6
Table 5.2 Recovery of radiolabelled steroids extracted from 
pooled racing greyhound urine.
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m1
Figure 5.3 Sample chromatogram showing the separation of 17p- 
Oestradiol and 17(3-Oestradiol glucuronide
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Metabolism of Testosterone in the Racing Greyhound
Following the unsuccessful attempts to establish a full urinary steroid profile in 
the male racing greyhound, it was decided to concentrate on the metabolism of 
testosterone and establish what was happening to one of the main androgenic 
steroids. This part of the study was divided into three parts:
The concentration of testosterone in the urine of untreated male greyhounds:
A dual approach was taken to determine the concentration of testosterone in the 
urine of the male greyhound. Single samples were extracted and split into two 
equal portions. Portion one was analysed using a commercially available 
radioimmunoassay (RIA) kit and portion two was analysed by gas 
chromatography-mass spectrometry in the selected ion recording mode.
Sample preparation:
Concentrated hydrochloric acid (2ml) was added to greyhound urine (5ml) and 
incubated at 80°C for 15 minutes. Following hydrolysis, the samples were 
neutralised using sodium hydroxide and extracted with dichloromethane (8ml). 
After separation of the two layers the dichloromethane was split into two equal 
portions, 3 ml in each portion. Portion A was analysed by RIA
Radioimmunoassay analysis:
The dichloromethane was taken to dryness under nitrogen at 60°C. The extracts 
were re-suspended in buffer supplied with the RIA kit (0.5ml). Into clean, plastic 
tubes, samples controls and calibrators (0.1ml), 125I-testosterone and testosterone 
antiserum were added. This was allowed to sit at room temperature for 60 
minutes. After incubation, Goat anti-rabbit globulin was added and the samples 
allowed to sit for a further 60 minutes. The samples were centrifuged at 2000g 
for 20 minutes and the supernatant decanted. The remaining pellet was
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counted in a Cobra Gamma counter (supplied by Canberra Packard) for 1 
minute. Concentrations of testosterone in the samples were calculated from a 
prepared calibration curve.
GC-MS analysis
Internal standard (androstane, 500ng/ml) was added to each sample. The 
dicholoromethane was taken to dryness under nitrogen at 60°C and the samples 
derivatised as described in chapter 4 for methoxime/TMS derivatives. Analysis 
was carried out monitoring the ions listed in table 5.3. A calibration curve was 
constructed (correlation coefficient of 0.9901) using the ratio of the areas under 
the curves of m/z 389 (testosterone) and m/z 260 (androstane).
Creatinine analysis:
As with almost all the experiments in this study, it was not possible to have 
complete urine collections. To try and standardise the urine concentrations and 
correct for variations in diurnal urine volume, creatinine concentrations were 
determined in all samples analysed as detailed in chapter 4.
Testosterone concentration by RIA
Figures 5.4a and 5.4b show the concentrations of testosterone in urine samples 
taken from two separate dogs. One line represents the raw data and the other is 
corrected for creatinine concentration. As can be seen form the graphs, in most 
cases when the results are corrected for creatinine concentration, the levels of 
testosterone in the urine samples are far more consistent. There are, however, 
differences in the concentration of testosterone per milligramme of creatinine 
between the two animals and a far larger population of animals should be studied 
to determine normal ranges.
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Compound Ions Monitored
Androstane 245.2269
254.9856 (lock mass)
260.2504
Testosterone 358.2566
380.9160
389.2750
Table 5.3 Ions monitored for the determination of testosterone in
urine.
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Testosterone concentration by GC-MS
Analysis of the second portion of the extracts by GC-MS was unsuccessful. A 
significant interfering peak sat over the testosterone peak making any meaningful 
interpretation of the concentration of testosterone impossible. The result 
demonstrated clearly that the solid phase extractions clean up procedures 
detailed in Chapter 4were required to obtain meaningful data. Due to lack of 
sufficient sample, it was not possible to repeat the above samples.
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Dosing with Radiolabelled testosterone.
Preparation of radiolabelled testosterone:
In order to investigate further the metabolism of testosterone in the racing 
greyhound, it was decided to dose an animal with a very small amount of 
radiolabelled testosterone of a high specific activity. By injecting this small 
amount, it was hoped that little disruption to the endogenous pool of steroids and 
consequently to the steroid metabolism would occur. Details of the experimental 
protocol are given in chapter 4. It was not possible to use trained greyhounds 
that were actively involved in racing for these experiments due to the use of the 
radiolabelled compound.
In addition, the original experimental protocol included the collection of faeces. 
The greyhound used for this radiolabelled study was effectively a house-trained 
animal. Even though the greyhound was not enclosed in its own kennel, it 
refused to defecate in its living environment. After three days, the animal was in 
such distress that it had to be let out of the cage to defecate. It was decided then 
to suspend faeces collection for the sake of the health of the greyhound.
Plasma concentrations:
Due to the very low concentration of testosterone given to the animal (ca.6 
nanogrammes), no attempt was made to identify the individual radiolabelled 
compounds. The level of radioactivity found in the plasma of the greyhound is 
given in figure 5.5. Using the initial portion of the graph, it is possible to make 
an estimation of the apparent volume of distribution of testosterone. When 
extrapolated this is calculated at 5.8 litres. It is known that the weight of the 
greyhound was 37.5 kilogrammes and that approximately 8% of the animal’s 
weight is blood volume. Therefor, this greyhound has an approximate blood 
volume of 3 litres. Consequently, approximately 50% of the given dose has left
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the blood and entered the tissues. Rather than a steady decline in the level of 
radioactivity, between 8 and 24 hours the levels rise again. This would indicate 
that some of the material is either being released back into the body from the 
tissues, or more likely that enterohepatic re-circulation is occurring and the 
radiolabelled material is being reabsorbed from the gut.
Levels of Radioactivity in the Urine:
24-hour total collection of urine was possible in the steel metacages. The results 
of the urine collection are given in figure 5.6. The results are expressed both as 
% dose eliminated in a given 24 hour period and cumulative dose excreted. 
Approximately 40 % of the total dose is eliminated in the urine within 144 hours 
post dose. 22 % of the dose is eliminated between 0 and 24 hours, falling to 
almost 10 % of the dose in the following 24-hour period. The remaining 8 % is 
excreted between 48 and 144 hours post dose. This long window of detection 
suggests that at least some of the radiolabelled material is being retained in the 
body in the form of testosterone or metabolites for an extended period. This 
extended period of detection again supports the hypothesis of enterohepatic 
recirculation of steroids in the racing greyhound.
Metabolism of deutero-labelled testosterone:
This part of the study was designed to enlarge significantly the amount of 
testosterone in the plasma of the racing greyhound and to allow an evaluation of 
the endogenous pool size of testosterone in the greyhound. The protocols for 
sample extraction and analysis are given in Chapter 4.
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In order to check the recovery of the testosterone from the plasma, plasma 
samples were spiked with levels of tritiated testosterone and the samples taken 
through the extraction procedure. The results of the extraction are given in 
Table 5.4. The mean recovery was 80%, with a standard deviation on the mean 
of the recoveries of 3.4% and a coefficient of variation of 4.9%_1.
1.92 milligrammes of the deuterium labelled was given to the greyhound. A 
graph of the ratio between the labelled and unlabelled testosterone is given in 
figure 5.7. After 15 minutes, the ratio of labelled material to unlabelled material 
was 10.5. When the concentration of the deuterium labelled material in the 
plasma was calculated, this gives an approximate plasma pool size for 
testosterone in the greyhound of 192 fig. This is about 6 times the reported value 
of about 35 pg in the human male. The 192 pg pool size seems quite large for a 
37 kilogramme greyhound. It is possible that in injecting the 2 milligrammes of 
material, the pool size was disrupted to such an extent that the apparent pool size 
is inflated.
Conclusions
There are little or no steroids excreted in the urine of a normal healthy male 
greyhound. This is consistent with many other species (cows, sheep, goat) but 
differs from the human. It is possible to determine the presence of testosterone 
in the urine of the male racing greyhound using radioimmunoassay, but due to 
the inherent crossreactivity of immunoassays, it is not possible definitively to 
quantify the testosterone in urine. If the assay is specific enough only to measure 
testosterone, the levels present are in the order of a few nanogrammes per 
millilitre of urine. These levels would be too low to definitively identify the
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presence of testosterone by full scan mass spectra with the equipment available. 
While the use of the labelled forms of testosterone have provided some 
information regarding the metabolism of testosterone in the male animal, a 
significant amount of work remains to be done. In the female animal, it was 
possible to determine a steroidal profile in urine. However, the presence of the 
steroids may be present due to the onset of oestrus rather than because they are 
present at all times.
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Chapter 6 Metabolism of Nandrolone and Boldenone
Introduction
Nandrolone (also known as 19-nortestosterone or trade name Laurabolin) and 
boldenone (also known as Dehydrotestosterone or trade name Vebonol) when this 
work was carried were thought to be two synthetic steroids which should not 
naturally be present in the urine of the racing greyhound. More recent information 
has suggested that nandrolone is, in fact, a naturally-occurring hormone in the 
horse89 and male pigs85. The structures of nandrolone and boldenone are given in 
Figure 6.1 along with those of the esters used in veterinary medicine.
The safety data sheet for Nandrolone Laurate (Laurabolin) states that this compound 
has marked anabolic and anticatabolic action with negligible androgenic or 
progestagenic activity. It is formulated to provide persistent activity (up to three
Oy'
weeks) following a single injection and is intended for prolonged anabolic therapy . 
The safety data sheet for boldenone undecylenate (Vebonol) states that Venonol is 
suitable for supportive treatment of all conditions in which it is desired to reverse 
weight loss. The compound is designed to stimulate the appetite of debilitated 
animals87.
Dosing of anabolic steroids
These preparations are normally given to animals in the form of an intramuscular 
injection. The esters are suspended in a nonpyrogenic oil base and injected into the 
greyhound in the hindquarters. The oil and esters are slowly absorbed into the body
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and it is recommended that a single intramuscular injection is given once every two 
weeks. Esterases in the blood then cleave the two sections of the molecule and 
allow the free steroid to circulate. Using an intramuscular injection avoids first pass 
metabolism of the liver that would inactivate the steroid. In these studies, the 
maximum recommended dose was given to two male racing greyhounds. A period 
of three months post dose was allowed between injections to allow the steroid 
biochemistry and metabolism of the greyhounds to return to normal.
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Nandrolone (19-nortestosterone)
C H 3  o - c — (CH2)10€H3
Nandrolone Laurate
Boldenone (1-dehydrotestosterone)
Figure 6.1 Structures of Nandrolone, Nandrolone Laurate and 
Boldenone
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Nandrolone.
The assay procedure for the final determination of nandrolone in plasma and urine 
samples is given in chapter 4. Prior to this methodology being established, several 
derivatives were prepared to determine which would be the most suitable for the 
analyses. During the initial evaluation studies, it was noted that nandrolone and 
epitestosterone chromatographed very similar retention times. When the mass 
spectrometer was operated in the selected ion monitoring mode at a resolution of 
3000, the M-15 peak of epitestosterone containing one carbon 13 atom gave a 
response on the ion chosen to monitor the molecular ion of nandrolone. This is not 
normally an problem. However, due to the similar chromatographic behaviour of the 
two compounds, it was possible that there would be a small but possibly significant 
contribution to the area of the nandrolone peak, giving an overestimation of the 
concentration of nandrolone in any samples analysed. Therefore a variety of 
derivatives were formed to try and separate these compounds.
Figures 6.2a,b, and c and Figures 6.3 show the mass spectra of the various 
derivatives of nandrolone and Figure 6.4 shows their structures.
Figure 6.2 shows TMS, MO-TMS and ethoxime-TMS derivatives of nandrolone. 
Most of the ions in Figures 6.2a and 6.2b are the same. These derivatives were 
formed in a similar manner to the other oxime-TMS derivatives described in Chapter 
4. The main differences in the mass spectra of the oxime derivatives occurred in the 
molecular ions (M+) and the M-90 fragment ions. These were simply due to the 
additional methylene group in the ethoxime derivative. The presence of a fragment 
ion at m/z 344 is due to the loss of the oxime moiety from the molecule.
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Figure 6.3 shows the reconstructed mass spectrum of the heptafluorobutyrate of 
nandrolone. This derivative was formed as described in chapter 4, along with the 
trifluororacetate and pentafluoropropionate analogues. The only major differences 
between the spectra of the three compounds was due to homologous series of 
fragment ions arising from the addition of extra CF2 groups to the steroid molecule. 
Of these derivatives, only the heptafluorobutyrate gave sufficient base line resolution 
of the compounds. Consequently, this was the derivative used for the determination 
of nandrolone in plasma and urine samples from the two male racing greyhounds. In 
addition to nandrolone, testosterone, epitestosterone, androsterone and 
etiocholanolone were determined. Of these compounds, only the 3-keto-A-4 steroids 
formed bis-derivatives. Compounds without a double bond in the A-ring 
(androsterone and etiocholanolone) formed the mono-derivatives.
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Trimethylsilyl of nandrobne
c h 3 X)—Si—C(CH3>3
R—O—N
Oxime-TMS derivatives of Nandrobne
R=CH3 Methoxyamine derivative 
R=CH2CH3 Ethoxyamine derivative
R—C—O
Perfluoroacyl derivatives of nandrobne
R=CF3, trifluoroacyl derivative 
R=CF 2CF3, Pentafluoroacyl derivative 
R=CF2CF2CF3, Heptafluoroacyl derivative
Figure 6.4 Chemical structures of nandrolone derivatives formed.
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Dosing of the Racing Greyhounds
A commercial preparation of nandrolone laurate (Laurabolin) was used to dose the 
greyhounds. The experimental protocol called for the collection of plasma samples 
predose and then at +lh, +2h, +3h, +4h, +5h, +6h, +8h, +24h, +2 days, +3 days, +7 
days, +7 days, +8 days, +9 days and +10days post dose. Urine samples were 
collected as and when produced. Complete urine collections were not possible for 
the reasons stated earlier. Blood samples were collected from the saphenous vein. It 
was hoped that it would be possible to time-trial the greyhounds at a local greyhound 
track while they were being affected by the nandrolone injection. However, on the 
advice of the professional trainer, the animals were not time-trialed as he believed 
the collection of blood samples would hinder and slow down the greyhounds and 
might have resulted in injury to the animals.
Dog 1 Dosing record and clinical signs
This animal weighed 33.5 kilogrammes at dosing and was given 1 millilitre of 
Laurabolin intramuscularly. This is the equivalent of 50 milligrammes of 
nandrolone laurate (1.5mg/kg) or approximately 30 milligrammes of nandrolone (0.9 
mg/kg). Blood samples were collected from the greyhound up to 5 hours post dose. 
No 6 hour sample was collected as it was becoming more and more difficult to 
collect a blood sample and a decision was made not to stress the animal unduly. It 
was still difficult to withdraw a blood sample for Dog 1 up to 7 days post dose.
After this time sampling became far easier. It is possible that the greyhound had 
relatively fragile veins which needed time to recover, and a relatively intensive 
sampling programme involving repetitive venipuncture may have been too
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aggressive. On day 2 of the experiment, the greyhound seemed stiff and 
uncomfortable and a small weight loss was noted. By three days post dose, the 
animal had returned to normal. This loss of form is likely to have been caused by 
the blood sampling rather than the effect of the dosing. As soon as the frequent 
hourly sampling was reduced, the greyhound’s condition returned.
Dog 2 Dosing record and clinical signs
This animal weighed 30.8 kilogrammes at dosing and was given 1 millilitre of 
Laurabolin intramuscularly. This is the equivalent of 50 milligrammes of 
nandrolone laurate (1.62 mg/kg) or approximately 30 milligrammes of nandrolone 
(0.97 mg/kg). Blood samples were collected from the greyhound up to 5 hours post 
dose. No 6 hour sample was collected as it was becoming more and more difficult 
to collect a blood sample from this dog also. A similar decision was made not to 
unduly stress the animal. There were no sample collection problems with dog 2 
after the 6 hour sample. Similar weight loss and stiffness symptoms were noted on 
day 2 of the experiment as for dog 1. These were gone by day three and the animal’s 
condition returned to normal.
Analysis of plasma samples.
Methodology for the analysis of the samples is given in Chapter 4.
In addition to the analysis of nandrolone, testosterone, epitestosterone, androsterone, 
etiocholanolne were determined. These compounds were used as internal markers 
of androgen metabolism and examined to see if they could be used to predict steroid 
doping. It has been suggested that determining the ratio of androsterone to 
etiocholanolone can be used to determine exogenous steroid administration88.
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Figures 6.5 and 6.6 show the concentration of nandrolone in the plasma of dogs 1 
and 2 respectively. As stated earlier, it was expected that nandrolone was an 
exogenous steroid to the greyhound. However, nandrolone was detected in the pre 
dose plasma samples examined. Dog 1 had an endogenous level of approximately 
60 ng/ml while dog 2 had a level of 30 ng/ml. Following the administration of 
Laurabolin to each dog a similar pattern was observed. The levels of nandrolone 
rose in the initial few hours post dose but fell below the predose concentration in the 
plasma. As time passed, plasma levels again rose to a maximum value of 154 ng/ml 
and 125 ng/ml for dog 1 and dog 2 respectively. A steady state concentration did not 
occur in the plasma and consequently the release of the nandrolone from the 
injection depot appeared to be episodic.
Figure 6.7 shows the level of testosterone in the plasma of dog 1 following 
administration of the steroid. In both greyhounds there was a significant drop in the 
concentration of testosterone in the plasma, which probably reflected suppression of 
the natural androgen production in the greyhound by the nandrolone.
Figure 6.8 shows the ratio of testosterone to epitestosterone in plasma for dog 1.
This figure shows an apparently good match between the plasma concentration of 
testosterone and the testosterone:epitestosterone (T:E) ratio for dog 1. The plasma 
T:E ratio is at its lowest when the concentration of nandrolone is greatest in dog 1. 
The levels of testosterone fell dramatically below the limit of detection for the assay, 
consequently, it was not possibly to determine if the same pattern existed for dog 2.
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This may provide the basis of a simple screen to determine if exogenous anabolic 
steroid have been given to a greyhound. Caution must be exercised however as this 
pattern was not repeated in the other greyhound and it may be an artefact caused by 
disruption to the natural androgen metabolism by the introduced nandrolone.
Figure 6.9 shows the ratio of androsterone to etiocholanlone for dog 2. As for 
testosterone and epitestosterone, the concentration of these compounds in plasma 
fell following the administration of nandrolone. It was not possible to determine a 
similar graph for dog 1 as the levels of androsterone and etiocholanlone fell below 
the limits of detection for the instrument. As can be quite clearly seen from the 
inserted trendline, there does not appear to be any significant change to this ratio in 
plasma. This ratio in plasma does not appear to be reliable as an indicator of 
anabolic steroid use in the racing greyhound. In addition, many trainers would 
probably find it unacceptable to ‘injure’ a racing greyhound by the collection of a 
blood or plasma before a race when such an injury may impair its ability to race. 
Sample collection after a race may be an option, but from the two greyhounds 
studied there may be some residual effect of more than one sampling is made.
Urinary Excretion of nandrolone 
Figure 6.10 shows the concentration of nandrolone (ng) per milligramme of 
creatinine and per millilitre of urine in the urine of dog 1. Nandrolone was present 
in barely detectable concentrations prior to the dosing of this dog. About 24 hours 
post dose there was an increase in the concentration of nandrolone (ng) per 
milligramme of creatinine to 0.39 nanogrammes nandrolone per milligramme 
creatinine. This fell over the next 10 days back towards the starting levels. A 
similar pattern existed for the concentration of nandrolone per millilitre of urine. A
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maximum concentration of 6.6 ng/ml of nandrolone was reached 48 hours post 
administration.
Figure 6.11 shows the concentration of creatinine in the individual urine specimens 
over an extended time period. The mean concentration of creatinine is plotted as the 
dotted line. As can be clearly seen, during the 11 day period after dosing, the levels 
of creatinine were continually below the average value for dog 1. This is probably 
due to the anticatabolic effect of the nandrolone, reducing protein metabolism and 
increasing the amount of protein retained within the body. Therefore, if a normal 
creatinine range can be established for dog 1 it would be probable that creatinine 
measurements could help in the identification of anabolic steroid use. It is 
questionable, however, if such an extrapolation could be made to other dogs. The 
greyhounds used in these experiments had free access to water at all times. In order 
to boost creatinine levels in a dog, all that would be required is to deprive the 
greyhounds of water for a period of time prior to collection of a urine specimen, 
therefore artificially raising the creatinine levels.
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The levels of other the steroids monitored were all below the limits of detection in 
both greyhounds.
As indicated earlier, there is very little data on the metabolism of anabolic steroids in 
the racing greyhound. The only other publication that deals with the topic in any
77detail is the previously mentioned publication of Brockwell et al . These authors 
gave an upper level of 19 ng/ml of nandrolone in the urine of a bitch 48 hours post 
administration and stated that they identified the presence of potentially two 
metabolites, 5a-estran-3p-ol-17-one and an unassigned oestradiol. Even when a 
bitch was given testosterone, the maximum level of testosterone was attained 2 days 
post administration and was only identifiable for up to three days post 
administration. The data presented here and that presented by Brockwell and co­
authors are consistent with each other.
At the beginning of this study, it was thought that nandrolone was a synthetic steroid. 
This study along with several others now suggests that nandrolone is, in fact, an 
endogenous steroid. Its presence has been reported in the colt89 and male pigs90. 
Therefor the presence of nandrolone or its metabolites must not be taken as evidence 
of use unless concentrations are also considered.
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B oldenone
Boldenone (1-dehydrotestosterone) was administered to two male dogs at a level 
of 1 millilitre of Vebonol. This is the equivalent of 25 milligrammes of 
boldenone undecylenate. As for nandrolone, analytical conditions are given in 
Chapter 4. Samples were collected as described for nandrolone above.
Plasma and Urine Results.
The presence of boldenone was not detected in any of the urine or plasma 
samples analysed. This is consistent with the report published by Brockwell et
77al . In addition, there did not appear to be the major disruption of the steroid 
metabolism that occurred with the nandrolone dosing experiment. There are 
several possible explanations for both the lack of detection of boldenone and the 
lesser effect on endogenous steroid metabolism.
Significantly less ‘free’ boldenone was effectively given to the greyhounds than 
nandrolone. Consequently, both the amount of boldenone available for excretion 
and the effects on the negative feedback mechanisms when applied to the 
androgen/steroid metabolism may well be less than those caused by the relatively 
higher concentration of nandrolone. In addition, it appears that in some species, 
boldenone is extensively metabolised. Dumasia et al5 reported 15 metabolites in 
the equine castrate, not including isomers. Consequently, depending on the 
metabolism of the greyhound, it may not be possible to detect any metabolites as 
each individual metabolite may be present at low concentrations.
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Conclusions.
It is possible to detect the presence of nandrolone in both the plasma and urine of 
racing greyhounds following intramuscular administration of this anabolic 
steroid as its laurate ester. Nandrolone has been shown to be an endogenous 
steroid in the greyhound. It appears that detection of administered steroids is 
dependent on both the steroid and the amount given. There does appear to be a 
suppression of the endogenous steroid concentration, as would be expected, and 
there may be a relationship between the plasma testosterone.epitestosterone ratio 
and the plasma testosterone concentration. The levels of creatinine appear to be 
depressed below the average shortly after dosing and this may provide a 
detection mechanism for a given animal.
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Chapter 7 The analysis of clenbuterol in the plasma and 
urine of the racing greyhound.
Introduction
Structures of clenbuterol and salbutamol are given in Figure 7.1
Mass Spectrometry Studies
Prior to extraction and analysis of the biological samples, it was 
necessary to determine sensitive, specific reliable methodology for the analysis 
of clenbuterol. A variety of derivatives were formed and the alternative mass 
spectrometry techniques available were evaluated to determine their suitability.
Derivative Formation Is Trimethylsilyl derivatives
Standard solutions of clenbuterol and salbutamol were taken to dryness 
under a stream of nitrogen at 60°C. BSTFA containing 1% TMCS (0.050ml) 
was added to each dried residue and sealed in a glass vial. Samples were 
incubated at 80°C for 30 minutes prior to analysis. Portions (lpl) of each sample 
were analysed by GC-MS system 1.
Derivative Formation 2: Perfluoroacyl derivatives
Standard solutions of clenbuterol and salbutamol were dispensed into 
glass vials and taken to dryness under a steam of nitrogen at 60°. Trifluoracetic 
anhydride, pentafluoropropionic anhydride or heptafluorobutyric anhydride 
(0.050ml) was added to form trifluoroacetyl (TFA), pentafluoropropionyl (PFP) 
and heptafluorobutyryl (HFB) derivatives respectively. The samples were 
allowed to stand at room temperature for at least 20 minutes prior to analysis. 
Portions (1 pi) of each sample were analysed by GC-MS using system 1.
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Clenbuterol
HOH2C
OH CH3
h - c h 2- n h —c —c h 3 
c h 3
Salbutamol
Figure 7.1 Structures of Clenbuterol and Salbutamol
GC MS Conditions
All analyses were carried out using GC-MS system 1 (as described previously in 
Chapter 4) with the following differences. A DB-5-MS Column (20m x 
0.18mm, df 0.18pm) was employed in the gas chromatograph. The reagent gas 
for the chemical ionisation, both positive and negative was ammonia (supplied 
by BOC, UK). For all full scan studies, the resolution of the mass spectrometer 
was set to 1000. For selected ion recording studies, the resolution of the 
instrument was set to 3000.
Trimethylsilyl derivative of clenbuterol.
The mass spectra of the trimethylsilyl (TMS) derivatives of clenbuterol 
and salbutamol are illustrated in Figure 7.2. The TMS derivative is formed by 
the action of the derivatisation reagent on the hydroxyl group to form only a 
mono-TMS derivative. Other authors have employed more rigorous 
derivatisation conditions (100°C for 16 hours) and have formed ^/^-derivatives 
of clenbuterol91. The second TMS residue attaches to the primary amine group. 
The base peak of the mass spectrum is at m/z 86 and corresponds to the cleavage 
of the side chain of the molecule -{CH2.NH.C(CH3)3]. The next most intense 
peaks are m/z 73 and m/z 57, corresponding to cleavage of the TMS group and 
the tertiary butyl group, respectively. A molecular ion couplet does not appear to 
be present at m/z 348/350 and the highest mass visible is at m/z 333/335, 
corresponding to the loss of a methyl group from the parent compound. Of the 
higher molecular mass peaks, those at m/z 262/264 (M-86) and m/z 243/245 (M- 
105) are the most intense. The former masses correspond to the loss of the side 
chain already detailed and the latter can be attributed to the loss of the -OTMS 
side chain plus a methyl group. It is well accepted that ions below m/z 100 are 
not particularly diagnostic. With the prevalence of these low mass ions in the 
mass spectrum of clenbuterol TMS derivative, it was decided to investigate 
alternative derivatives and mass spectrometric techniques.
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Perfluoroacyl derivatives.
Several other derivatives have been proposed for the analysis of 
Clenbuterol. Dumasia and Houghtan formed cyclic dimethylsilylmethylene 
derivatives and employed electron impact ionisation to look at a variety of (3- 
agonists, p-antagonists and their metabolites in the urine of horses9. Girault et al 
formed acid anhydride derivatives and employed mass spectrometry and negative 
ion chemical ionisation to determine the level of clenbuterol at femtomole 
sensitivity in the plasma of humans8. Due to the lack of information on the 
pharmacokinetics of p-agonists in the racing greyhound, and with the previous 
experience of the low levels of steroids in both urine and plasma of racing 
greyhounds, it was considered appropriate to maximise the sensitivity of the 
analyses and it was decided to use perfluoroacyl derivatives in combination with 
negative ion chemical ionisation (NI-CI) mass spectrometry.
As indicated above, Girault et a l8 formed perfluoroacyl derivatives and 
used pentafluorpropionic anhydride to form pentafluoropropionyl (PFP) 
derivatives. The authors justified the use of these derivatives, NI-CI and the 
extensive time commitment required by stating that the very low doses of 
clenbuterol given therapeutically (approximately 40pg/day) and the high volume 
of distribution of clenbuterol (approximately 350 litres) resulted in very low 
plasma concentrations. Following incubation at room temperature, they 
proposed the formation of a bis derivative, with rapid degradation to a mono 
derivative and an accompanying dehydroacylation within the clenbuterol 
molecule. The reaction scheme is summarised in Figure 7.3. They stated that it 
was possible to form a ^-derivative by incubation of the reaction mixture at 
higher temperatures, but a mixture of mono- and bis-derivatives was formed and 
the ratio between these two derivatives was not consistent
Page 133
h2n
OH H H
C -C -N -C (C H 3)3
c f3
I
c f2
I
CO
c f3
I
c f2
0  H CO
1 I I
C -C -N -C (C H 3)3 
H H
v
h 2n
H H CO
I I I
C = C -N -C (C H 3)3
Figure 7.2 Derivatisation of Clenbuterol as Proposed by
Girault et a l100
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Figure 7.3 Proposed Derivatisation reaction of Clenbuterol in
this studv
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In the present study, initial attempts to form and identify the mono- derivatives 
were unsuccessful. In all the analyses carried out using any of the perfluoroacyl 
anhydrides, ^/^-derivatives were invariably formed and these were accompanied 
by the dehydration proposed by the previous authors to give a ^/5-derivative. It 
was not possible to show the presence of a mono-derivative. This reaction 
scheme is illustrated in Figure 7.3.
Figures 7.5a, b, and c show the reconstructed mass spectra of TFA, PEP 
and HFB derivatives of clenbuterol respectively under positive ion electron 
impact conditions. Differences in the fragmentation patterns for each derivative 
are accounted for by the different lengths of the side chains of the derivatives.
Figure 7.6 illustrates the positive ion chemical ionisation mass spectra of 
the TFA and HFB derivatives. The HFB derivative has a base peak of 651 (M+1) 
and a higher mass at m/z 668 (M+18), corresponding to the addition of NH4+.
The TFA derivative also exhibits the (M+l) fragment at m/z 451 but there was 
no indication of a comparable (M+18) fragment at m/z 468. In addition, 
considerable fragmentation exists for the TFA derivative compared to the HFB 
derivative, resulting in the presence of a large number of diagnostically poor 
lower masses.
Figures 7.7a, b, and c show respectively the reconstructed mass spectra of 
TFA, PFP and HFB derivatives of clenbuterol under NI-CI conditions. There are 
both similarities and differences between the three derivatives. Differences 
between the spectra of the PFP and HFB derivatives can be explained by the 
differences in acyl groups attached to clenbuterol by derivatisation. A 
pseudomolecular ion at (M-l) caused by proton abstraction by the reagent gas 
exists for both compounds along with the loss of a fluorine atom (M-l9) and 
hydrogen chloride (M-36). The base peaks of both derivatives correspond to a 
loss of the tertiary butyl group and hydrogen fluoride (M-77). The second most 
intense peaks correspond to the loss of the previously mentioned groups and HC1 
(M-l 13). The TFA derivative, however, displays neither a
Page 136
Fi
gu
re
 
7.4
 
M
as
s 
Sp
ec
tr
i 
m 
of 
the
 
T
ri
m
et
hy
ls
ily
l 
de
ri
va
tiv
e 
of 
C
le
nb
ut
er
ol
SPESUB00 #1 x l  Bgd=0 
BpCl=0 1=1. lmus Hm=454 TIC=0
0 *TCLEN#64-0:TCLEN#61 
100-,
90_ 
80_ 
70 _ 
6 0 .  
5 0 .  
4 0 .  
3 0 .  
20 .  
10 .  
0
♦0:00:00 
SU Rent •
325
PT= 0°
S y s !
CaL :
S#1 1 .0
5139000 
1117000
297
100
165 184
JL  ll.i t.
150 200
262
_lJL,—L I __
250 300
450
394
359
JL_-U
435
PlflSS
350 400 450
Figure 7.5a Positive Ion Electron Impact Mass 
spectrum of the TFA derivative of Clenbuterol
SPESUB00 #1 x l Bgd=0 
BpPl=0 1=1.9mvs Hm=555 TIC=0
D = PCLEN451 -0  * PCLEN#44 
1001,
90
80_
70_
60_
5 0 .
40_
3 0 .
20_
10 -
0
♦0!00:0 
SU Rent =
375
PT= 0°
347
Sys:
CaL :
S#1 1 .0
27373000
550
431
RRS3
100 150 200 250 300 350 400 450 500 550 600
Figure 7.5b Positive Ion Electron Impact Mass 
I spectrum of the PFP derivative of Clenbuterol
SPE9UB00 #1 x l Bod=0
8p['l=0 I=69£ kvs Hm=654 
HELC2021»372-MELC*021#363
TIC=Q *0:00:0 5U Rent
PT= 9°
SO­
SO.
50_
481
65020.
635
10 .
57,5 594 614
650600550450
Sus: 
CaL : 
Sttl 1.02851000
4650O0
(HRSS
Figure 7.5c Positive Ion Electron Impact Mass 
spectrum of the HFB derivative of Clenbuterol
T 1 R x L. ! i 2 =390 20-JflN -93 14:53*0=15=17 70-250S C l*
BpPl-,4 I - i . 5 v  Hm=456 TIC=31146000 flcnt = Sus=KEITHl
GC= £49° C a t=19JANCI
100"  .
#481 1 .0
144 492000
5 0 :  2 j5
e i l i l i i l  lifciililij
369
3.\5 451j  JL  nflss
s # i 1 .0  
492000
Figure 7.6a Positive Ion Chemical Ionisation Mass 
spectrum of the TFA derivative of Clenbuterol
SFE3UB00 #1 x l  Bod=0 
BpPl=0 1=1.5mvs Hm=67£ TIC=0 
C = NELC4#3S6-C = NELC4#335 
100«
90 _ 
30 _ 
70 _ 
60 _ 
50 
40 _j 
30 _
C0_
10 .
0
100 2O0 300
*0 = OB;0 
SU flcnt
PT= 0° 
651
by s CaL
S#1 1 .0
2155100O  
637000
400 500
I .6681, a a u. HRS:
600 700
Figure 7.6b Positive Ion Chemical Ionisation Mass 
spectrum of the HFB derivative of Clenbuterol
iPE'i'Ufyu tti x l Bod=0 
BpP1=0 I= 2 24 j^ s  Hrn=438 TIC=0 
C = MEGCLE#75-C = NEGCLE#72
-V j : O'.'I : 0 0  
SU flc n t:
33710"
9 0 -
80_
7 0 -
5 0 -
40_
3 0 -
20 - 378
30310 -
20 450150 400100 350
Sys:
PT= 0° CaL:
S#1 1 .0
3289000
PlflSS
Figure 7.7a Negative Ion Chemical Ionisation Mass 
spectrum of the TFA derivative of Clenbuterol
100— 473
37310000
50
RflSS
100 200 30O 400 500 600 700 800
Figure 7.7b Negative Ion Chemical Ionisation Mass 
spectrum of the PFP derivative of Clenbuterol
SPE3U800 ttl x l Bod=0 
BpPl=0 1=4 .Grnvs Hm=653 TIC=0  
C:HELC5#363-C:HELC5#36Q 
100 ■
SO­
SO
7 9 -
6 9 -
5 9 -
4 0 _
SO­
SO-
10 -
9
*9 s 90 • 09 
SU flc n t:
573
PT= 0°
5% /
100 £00 300 400 500
614
L \ l X
600
Sus ■ 
Cat =
>#1 1.0 
58580U00
PlflSS'00
Figure 7.7c Negative Ion Chemical Ionisation Mass 
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pseudomolecular ion nor the (M-77) ion. The ions corresponding to (M-36) and (M- 
113) losses do exist, however.
The sensitivity of the assay was determined using the HFB derivative under 
NI-CI conditions. The GC-MS system 1 was operated in the selected ion recording 
mode at a resolution of 3000. The ions monitored were the molecular ion (m/z 573 
and m/z 537),. Using these parameters, it was possible to determine the presence of 
lpg of clenbuterol injected onto the column. Any concentrations lower than this 
resulted in a signal to noise ratio of less than 3:1.
Using NI-CI mass spectrometry in association with HFB derivatives, it was 
possible to achieve good selectivity and sensitivity. To achieve and maintain this 
level of sensitivity, however required a disproportionate amount of time for 
maintenance. When analysis of the samples commenced, it was noted that sufficient 
sensitivity and specificity could be achieved using GC-MS system 2 in the electron 
impact mode. All analysis of biological samples were therefore carried out using the 
alternative GC-MS system 2 in conjunction with TMS derivatisation.
Pharmacokinetic Studies
Details on dose preparation, animal dosing, sample collection and analysis 
are given in Chapter 4.
Additional Experimental Details
Calibration standards were prepared by extraction of standards from urine 
and plasma. Correlation coefficients for all calibration curves were in excess of 
0.99. All samples were analysed in duplicate. Each result had to be within 5% of 
the average of the two values.
7.3 Results and Discussion
Figures 7.8 and 7.9 show the concentrations of clenbuterol in the plasma of a dog 
and a bitch respectively versus time after dose. Peak levels for both animals
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appeared to be approximately 5 hours post dose, reaching concentrations of 62ng/ml 
in the dog and 50ng/ml in the bitch. Within 24 hours, plasma concentrations in both 
animals had fallen to 2ng/ml. Levels then continued to decline fairly steadily after 
24 hours until 168 hours post dose when it was no longer possible to determine the 
presence of clenbuterol in the plasma of either animal. Between 24 and 168 hours, 
clenbuterol displayed a half life of approximately 24 hours in the plasma of both 
animals.
Levels of clenbuterol in urine were, as expected, significantly higher than in 
plasma. As with the experiments with nandrolone and boldenone, it was not possible 
to obtain complete urine collections. The results presented in Figure 7.10 and 7.11 
show the levels of clenbuterol found per millilitre of urine and per milligram of 
creatinine for the dog and bitch respectively. When comparing the two animals, a 
similar urinary excretion pattern was found to exist. When the results were corrected 
for ‘dilution’, it can be seen that there was approximately three times the 
concentration of clenbuterol per milligram of creatinine in the samples obtained 
from the bitch when compared to the dog (approximately 12.8 ng/mg creatinine vs. 
4.3 ng/mg creatinine). For both animals, similar amounts of clenbuterol were 
present in the 24 and 48 hour samples. The male greyhound urine sample had a 
concentration of 4.3ng/ml and 4.4 ng of clenbuterol per mg creatinine at 254 and 48 
hours respectively, falling to 0.5 ng/mg creatinine by 96 hours. For the female 
greyhound levels of 12.8 and 11.1 ng/mg creatinine were present at 24 and 48 hours 
post dose and this fell to 0.89 ng/mg creatinine 72 hours. Levels of clenbuterol 
continued to fall after these initial time periods. It was still possible to determine the 
presence of clenbuterol 10 days following administration.
Two milligrams of clenbuterol were administered to each animal, giving an 
approximate dose of 0.0625mg/kg.. Zimmer et al used 14C-labelled clenbuterol to 
dose 5 rabbits and one 11 kg beagle at 2.5mg/kg. This level is equivalent to 27.5 mg 
for an 11 kg dog or 80 mg for a 32 kg greyhound. No side effects were reported in 
either species and the majority of the radioactivity was excreted in the urine by 96
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hours post dose . Koyama et al also gave up to 2.5 mg/kg/day of clenbuterol to 
beagles with no notable side effects. For comparison Girault et al 8 administered a 
dose of 40 pg per day to healthy human volunteers and Dumasia and Houghton 9 
administered 800pg daily for four days to horses. Although the dose used in this 
study appears to be high in comparison to these doses, it was believed to be 
consistent with the significantly higher doses used by individuals who abuse 
performance-enhancing substances.
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In the greyhounds, however, this dose produced major side effects. 
Contraindications appeared approximately 2 hours post dose. Heart rate and 
respiration were both dramatically increased. Both animals became polyuric and 
polydipsic. Due to the severity of these side effects, blood sampling was suspended 
5 hours post dose to avoid any additional stress to the greyhounds. Creatinine levels 
fell in the urine to such low levels the it was not necessary to perform the normal 
thirty fold dilution for creatinine analysis, a consequence of the polyurea and 
polydipsia. Blood sampling was resumed 24 hours post dose and, although 
dramatically reduced, the side effects were still present All side effects ceased by 
48 hours post dose.
These dramatic side effects may be due to several factors. As indicated 
earlier, it is not possible to create a (3-agonist which only stimulates a single 
adrenoceptor sub-type. The symptoms displayed by both greyhounds reflect the 
stimulation of the adrenoceptors and the activation of the ‘flight or fight’ response, 
as reflected by the increased heart rate and respiration. It is possible that the 2 
milligram dose was excessive for dogs, which is unlikely as far larger doses were 
given to beagles with little or no side effects, or that greyhounds may be particularly 
sensitive to stimulation of the adrenoceptors. In addition, both animals were fully 
trained race-fit animals with very little body fat. The high volume of distribution of 
clenbuterol in humans(ca. 350 litres) reflects the distribution of the drug throughout 
an individual. If the drug was less distributed in the racing greyhound, any side 
effect could be significantly greater.
The greyhounds used for this metabolism study were trained racing 
greyhounds. It would be useful to give a reduced dose of clenbuterol to both an 
actively training greyhound and a ‘pet’ - an unfit, fat greyhound - to see if the 
different responses could be attributed to the training regime.
In other breeds of dog, peak plasma levels reached 1.25 ng/ml 2 to 3 hours 
post administration of a dose of 2.5 mg/kg and the majority of the dose was excreted 
from the plasma by 9 hours post dose92. As indicated earlier, urine levels were
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almost non-existent 96 hours post dose. In 10 human volunteers, under normal 
therapeutic dosing conditions, a 20pg dose produced a mean peak plasma level of 
86.5 pg/ml approximately 2.5 hours post oral dose 8, a similar time to that previously 
reported for the dog. The half life was reported as 29.5 hours with significant levels 
of clenbuterol still detected 72 hours post-dose. No data was presented on urine 
levels. In horses, an 800pg dose for 4 days could be detected in urine using the 
relatively insensitive technique of full scan electron impact ionisation mass 
spectrometry up to 96 hours after the final dose9. No information was given on 
plasma levels.
It is well known that it is difficult to extrapolate pharmacokinetic data 
between species. In these studies there appear to be significant intra-species 
variation as well as inter-species similarities. In the beagle, two studies revealed 
little or no side effects at significantly higher doses than those used in this study.
This level in greyhounds produced significant side effects. The half-life of 
clenbuterol in humans and greyhounds appears to be similar at 29.5 and 24 hours 
respectively. No information is available regarding the plasma half-life of 
clenbuterol in either the beagle or the horse. Due to the side effects of the dose, it 
was not possible to determine the exact time for peak plasma concentration in the 
racing greyhound due to the interruption of the plasma sampling schedule.
However, it does appear to be at least 5 hours post dose, significantly longer than in 
either the beagle or human. The pattern of urinary excretion is similar in both dog 
breeds, with the majority excreted by 48 hours post administration. It would appear 
that an extended period of elimination exists in the greyhound and possibly the 
horse, as it is possible to detect the presence of clenbuterol by full scan electron 
impact mass spectrometry up to 96 hours post dose.
The longer detection time of clenbuterol in urine samples of the greyhounds 
when compared to horses may be due to the larger dose of clenbuterol given to the 
greyhounds and the relatively small volume of urine eliminated by the dogs, 
effectively concentrating the urine sample.
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In conclusion, following a single, oral 2 milligram dose of clenbuterol it is 
possible to detect the drug in the plasma of a racing greyhound for up to 7 days and 
in the urine for up to ten days. The two milligram dose produced significant side 
effects in actively trained racing greyhounds, which had not been suggested by 
previous studies in beagles.
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Chanter 8 Conclusions
This project was designed to examine the metabolism of anabolic agents in the 
racing greyhound. Six targets were set and each of them can be dealt with 
separately.
To establish a metabolic unit for greyhounds in which dogs would be trained 
in an identical manner to racing animals.
Previous projects within the Department of Forensic Medicine and Science, 
University of Glasgow have always used greyhounds that were effectively pet dogs 
and kept at the Veterinary Medicine School. These animals were caged and used to 
being handled. They were, however, quite old animals and had been used for 
multiple metabolism experiments. Consequently, the collection of samples from 
these animals has been relatively easy and it was possible to keep the greyhounds in 
metacages that would permit total urine collections. In addition, for serial sampling, 
indwelling cannulae could be used. This reduced significantly the amount of 
damage caused by repeated venipuncture.
In the present work, only the radiolabelled-testosterone dosing experiment used a 
captive animal in a metacage, and that was for health and safety reasons. Safety 
regulations would have been breeched if radioactive urine and faeces were allowed 
to contaminate the kennel environment.
The aim of using actively training greyhounds was to determine the metabolic 
profiles of actual racing animals and to determine if the use of anabolic agents could 
in reality improve the track times of the individual animals. Subtle differences may
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exist between trained and untrained animals. The sampling regime however, which 
involved venepuncture, damaged the animals and on the advice of the trainer the 
animals were not time trialed. The trainer felt that it was possible that more serious 
injury could result if these animals were trialed. When the animals were not being 
used for the metabolism experiments, however, they were treated exactly as the 
other greyhounds prepared for racing by the trainer.
The greyhounds were kennelled approximately 60 miles from the Department and 
the metabolism experiments were carried out under Home Office Licence at the 
kennels. These settings were not ideal. As stated earlier, it was not possible to 
obtain complete urine collections. This would have been advantageous and may 
have allowed for a more detailed determination of the elimination profiles of the 
greyhounds. When blood samples were collected, it was not always possible to 
separate the plasma from the red blood cells as quickly as would be preferred. Some 
lysis of the red blood cells could occur. A small centrifuge was supplied to the 
kennels to overcome this problem. A local veterinary nurse was required to come 
and collect the blood samples. Due to her working pattern, it was not always 
possible to collect all the desired samples, especially samples times that occurred 
over the weekend. In a more controlled environment a more appropriate sampling 
protocol could have been employed, although it may not have been possible to train 
the greyhounds.
In spite of these problems, it was possible to use the greyhounds for the metabolism 
experiments in the training environment. It may have been interesting, however to 
have compared the metabolic profiles between the racing greyhounds and the ‘pet’ 
to determine if there were any major differences caused by the training regime.
Page 152
To characterise the normal urinary and plasma steroid profiles for the 
racing greyhound.
To summarise, the levels of steroids present in the plasma of the male and female 
racing greyhound appear to be extremely low. Unlike humans, it was not possible to 
determine a normal urinary or plasma steroidal profile using full scan mass 
spectrometry in the male racing greyhound. It was possible, however, to detect the 
presence of some steroids in the female. The presence of these steroids in the 
female may be an indicator of the onset of oestrus. Using selected ion monitoring, it 
was possible to determine the presence of some steroids (testosterone, 
epitestosterone), but at levels of a few nanogrammes per millilitre. Levels of 
testosterone determined by radioimmunoassay corroborated these mass spectrometry 
findings. Therefor, unlike humans, greyhounds do not appear to have significant 
amounts of steroids in their plasma or urine.
To obtain some basic pharmacokinetic information regarding steroid 
metabolism in the racing greyhound.
Using labelled forms of testosterone it was possible to determine some 
pharmacokinetic information from male greyhounds. It appears that testosterone is 
rapidly removed from circulation following the intravenous dosing of a small 
amount of radiolabelled testosterone. It also appears that enterohepatic recirculation 
occurs, suggesting that at least some of the testosterone is eliminated via the bile. 
Only 40% of the radioactivity was recovered in the urine up to 7 days after dosing 
and this level seems to have plateaued. This suggests that up to 60% of the dose is 
eliminated via the faeces. Administration of deuterium labelled testosterone to a
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greyhound gave a dilution factor which suggested a pool size for testosterone of 
approximately 190 jug. This pool size is between 5 and 6 times that of a human male 
and appears to be disproportionaly large. It may be that the administration of such a 
large deuterium labelled dose totally disrupted the steroid metabolism of the 
greyhound and that this pool size should be regarded with caution. If such a large 
pool of testosterone existed, it would be expected that some metabolites of 
testosterone could be detected in urine samples. As discussed earlier, however, there 
were little or no steroids detected in the urine samples analysed.
To examine the pharmacokinetics of specific anabolic steroids in the racing
greyhound.
Nandrolone and boldenone were given to two male racing greyhounds and the urine 
was analysed for the presence of the parent compounds. It was noted that 
nandrolone appeared to be present prior to the doping of the animals, suggesting that 
nandrolone is in fact an endogenous steroid to the racing greyhound. This is 
consistent with findings in other species 89,90 The concentration of nandrolone 
found in the urine was extremely low. The lack of boldenone in the urine sample 
along with the low concentrations of nandrolone suggest that the steroids are 
extensively metabolised prior to excretion, or else, like testosterone, are excreted in 
faeces. In one of the few papers dealing with steroids and the racing greyhound, 
Brockwell and co-workers had similar findings, including the presence of 
testosterone for only two days after dosing with testosterone.72
Page 154
To examine the effects of exogenous steroids on the natural steroid profile of 
the racing greyhound.
The administration of nandrolone and deuterium labelled testosterone appeared to 
depress the levels of steroids found in plasma and urine samples. During the 
nandrolone experiment, the steroid profile of one greyhound appeared to be 
completely eliminated. This loss was probably caused by the negative feedback 
loops within the pituitary-hypothalamus-gonadal axis of the animals. In addition to 
the suppression of the steroid levels there appeared to be a suppression of the 
creatinine eliminated from the body as the nandrolone exerted its anticatabolic 
effect. The elimination of creatinine appeared to return to normal after 
approximately 10 to 12 days. While this may be an inexpensive way to determine 
the administration of an anabolic steroid to an individual animal, it is likely to be 
unspecific and of little practical use when the normal ranges of creatinine for the 
greyhound are established. Boldenone appeared to have a significantly lower effect 
on the steroid profile of the racing animals, possibly due to the lower does applied. 
The use of internal markers to determine anabolic steroid use, such as the T:E ratio 
was unsuccessful in these studies but recent publications suggest that internal 
markers can be used to determine the exogenous administration of endogenous 
steroids such as testosterone94.
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To examine the pharmacokinetics of other anabolic agents in the racing 
greyhound
Clenbuterol was chosen as a model non-steroidal anabolic agent. The dose given to 
one male and one female greyhound caused very severe side effects. It was possible 
however to determine the presence of clenbuterol in the plasma and urine sample for 
an extended time period (at least 10 days) post dose. The clinical indications 
corresponded to the known side effects of beta agonists.
Future Work
It does appear that there are some unique features regarding the metabolism of 
steroids and other anabolic agents in the racing greyhound. These features may be 
applicable to the canine species in general or may be applicable specifically to the 
greyhound. These features may arise as a result of persistent inbreeding to create the 
current form of racing greyhound. As a consequence of inbreeding other species of 
dog have acquired genetic traits. Dalmatians, for example, are prone to be deaf at 
birth and have chronic kidney problems. It may be that the lack of steroids in the 
urine and the sensitivity of greyhound to beta agonists are as a result of genetic traits. 
It is also possible that the differing responses may be due to the training regime 
employed.
Consequently, it would be appropriate to investigate the steroid profile and 
metabolism of anabolic steroids and anabolic agents both in untrained greyhounds
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and other species. This would help resolve the issues surrounding particular 
susceptibilities to certain drugs.
In future studies of greyhound steroid biochemistry, more sensitive methods would 
be required than those available for the work presented in this thesis, and this is 
likely to be possible if newer instrumentation were to be used. Also, the present 
study provided some indications that steroids are excreted via bile into the faeces. 
Other drugs are known to be excreted in faeces in the dog, for example non-steroidal 
anti-inflammatory drugs95. Future pharmacokinetic studies on the greyhound should 
incorporate faecal analysis as part of the study plan for this reason. The disturbances 
to the normal greyhound steroid biosynthesis noted in the present work require 
further investigation, to elicit the factors controlling endogenous synthesis and how 
these are disrupted in the greyhound by administration of anabolic steroids. This 
would be essential if screening methods similar to those used in the human for 
steroid doping are to be developed. The analytical scheme for future studies should 
therefor include peptide hormones.
Although two anabolic steroids and one beta agonist have been studied here, it 
would be appropriate to extend the range of compounds studied. Suggested 
compounds include estradiol, zeranol, stanozolol and other beta agonists. If 
additional studies were to be carried out, it would be easier to use a combination of 
unlabelled, deuterium labelled and radiotracer material simultaneously. This was 
not possible in the present study, as the aim was to use actively trained racing 
greyhounds
Overall, the aims of the study were met, and provide starting points for future work.
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